WO2008061373A1 - Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues - Google Patents

Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues Download PDF

Info

Publication number
WO2008061373A1
WO2008061373A1 PCT/CA2007/002118 CA2007002118W WO2008061373A1 WO 2008061373 A1 WO2008061373 A1 WO 2008061373A1 CA 2007002118 W CA2007002118 W CA 2007002118W WO 2008061373 A1 WO2008061373 A1 WO 2008061373A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclohexanehexol
secretase inhibitor
alkyl
compound
disease
Prior art date
Application number
PCT/CA2007/002118
Other languages
English (en)
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc. filed Critical Waratah Pharmaceuticals Inc.
Priority to JP2009537460A priority Critical patent/JP2010510254A/ja
Priority to CA002670405A priority patent/CA2670405A1/fr
Priority to US12/445,164 priority patent/US20100292157A1/en
Priority to EP07845583A priority patent/EP2091566A4/fr
Publication of WO2008061373A1 publication Critical patent/WO2008061373A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates generally to compositions, conjugates, and methods comprising a cyclohexanehexol and a secretase inhibitor, and uses thereof.
  • Amyloid-beta peptides exist in two forms - 40 amino acid long peptides and 42 amino acid long peptides. The differences in peptide length result from differential cleavage of the amyloid precursor protein (APP). The 42 amino acid peptides are derived from cleavage of APP by both beta- and gamma-secretases (Sinha and Lieberburg (1999) Proc. Natl. Acad. Sci. USA 96, 11049-11053).
  • the principal beta-secretase in neurons is the aspartic protease BACEl (also known as Asp or Memapsin) which cleaves APP to release the NH 2 terminus of the beta-amyloid peptide (Sinha et al., 1999, Nature 402:537-554; PCT application WOOO/17369). Subsequent cleavage by the gamma-secretase releases the COOH terminus of the peptide.
  • the gamma-secretase is a high molecular weight complex which is composed of Presenilin 1 (PS 1 ), mature Nicastrin, APH- 1 , and Pen-2 (Kimberly, W.T. et al., 2003) Proc. Natl.
  • Beta- and gamma-secretases have been targeted for the development of therapeutics.
  • Other therapeutic approaches are being developed based on accelerating the removal of A ⁇ or preventing its aggregation and/or toxicity.
  • One such approach involves administration of one or more cyclohexanehexol compounds, such as scyllo-inositol compounds (PCT WO 2004/075882 to McLaurin)
  • the present invention relates to a class of compounds that may be especially effective in the treatment of Alzheimer's disease when combined with a cyclohexanehexol or similar compound.
  • the class of compounds is secretase inhibitors, in particular selective beta- secretase inhibitors and selective gamma-secretase inhibitors, especially beta-secretase inhibitors.
  • the invention provides compositions, conjugates, and methods (e.g. combination therapies) comprising one or more cyclohexanehexol, especially a scyllo- inositol compound, and one or more secretase inhibitor, especially one or more beta-secretase inhibitor.
  • compositions, conjugates, and methods provide beneficial effects in the treatment of diseases for which a cyclohexanehexol especially a scyllo-inositol compound, and/or a secretase inhibitor have a therapeutic effect, including diseases characterized by amyloid deposition, in particular Alzheimer's disease and similar diseases.
  • the invention relates to compositions, conjugates, and methods for the prevention, intervention, and/or treatment of a condition comprising a therapeutically effective amount of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in particular a therapeutically effective amount that provides beneficial effects.
  • a composition, conjugate, or method comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, employing different mechanisms to achieve maximum therapeutic efficacy, may improve tolerance to the therapy with a reduced risk of side effects that may result from higher doses or longer term monotherapies (i.e. therapies with each compound alone).
  • a treatment of the invention can permit the use of lower doses of each compound (in particular aspects lower doses of a secretase inhibitor) with reduced adverse effects of each compound.
  • a suboptimal dosage may provide an increased margin of safety, and may also reduce the cost of a drug necessary to achieve prophylaxis and therapy.
  • a treatment utilizing a single combination dosage unit may provide increased convenience and may result in enhanced compliance.
  • Other advantages of a composition, conjugate, or combination therapy may include higher stability towards degradation and metabolism, longer duration of action, and/or longer duration of action or effectiveness at particularly low doses.
  • compositions, conjugate, or method comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, may significantly reduce beta amyloid deposits in the brain (beta-amyloid plaques) and cerebral blood vessels (beta amyloid angiopathy).
  • a treatment of the invention may be sustained over several years thereby having a major beneficial impact on the severity of the disease and its complications.
  • the invention contemplates a composition, in particular a pharmaceutical composition, comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor.
  • a pharmaceutical composition may optionally comprise a pharmaceutically acceptable carrier, excipient, or vehicle. More specifically, the invention provides a composition for treating and delaying the onset of neurodegenerative diseases.
  • a composition of the invention has one or more cyclohexanehexol and one or more secretase inhibitor, and optionally one or more pharmaceutically acceptable carriers.
  • the invention also contemplates a pharmaceutical composition, comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor that provides beneficial effects relative to each compound alone.
  • the beneficial effects provided by a composition of the invention can include enhanced therapeutic effects, in particular sustained therapeutic effects.
  • the beneficial effects provided by a composition of the invention can include inhibition, reduction, or reversal of A ⁇ fibril assembly or aggregation, A ⁇ toxicity, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils.
  • Beneficial effects may also include the reduction of at least one symptom of a disease, or preventing an increase (or slowing the rate of increase) in or delaying the onset of, at least one symptom of a disease.
  • a composition of the invention can be in a form that results in disruption of aggregating A ⁇ , reduced cerebral accumulation of amyloid ⁇ , deposition of cerebral amyloid plaques, soluble A ⁇ oligomers in the brain, glial activity, inflammation, and/or cognitive decline in the subject.
  • a composition can have increased bioavailability (absorbed more rapidly and to a higher degree) or provide enhanced therapeutic effects.
  • a treatment of the invention may be sustained over several days, weeks, months or years thereby having a major beneficial impact on the severity of the disease and its complications.
  • the invention also provides a pharmaceutical composition for the treatment of a disease comprising a therapeutically effective amount of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, to provide a sustained beneficial effect following treatment in a pharmaceutically acceptable carrier, excipient, or vehicle.
  • a pharmaceutical composition comprising a scyllo-inositol compound, and a beta-secretase inhibitor is provided which has - A - been adapted for administration to a subject to provide beneficial effects to treat a disease.
  • the composition is in a form such that administration to a subject results in reduction in A ⁇ levels in the subject for a sustained period of time after cessation of treatment.
  • the invention features a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially beta-secretase inhibitor, in dosages effective for inhibiting, reducing, reversing, or disrupting A ⁇ fibril assembly or aggregation, A ⁇ toxicity, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils, in particular for a sustained period following administration of the cyclohexanehexol, especially scyllo-inositol compound and secretase inhibitor, especially beta-secretase inhibitor.
  • the invention features a composition
  • a composition comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in a dosage effective for disrupting aggregation of A ⁇ , increasing inhibition of long term potentiation induced by A ⁇ oligomers and/or maintenance of synaptic function, and/or for reducing cerebral accumulation of amyloid ⁇ , deposition of cerebral amyloid plaques, soluble A ⁇ oligomers in the brain, glial activity, inflammation, and/or cognitive decline in the subject, in particular for a sustained period following administration of the composition.
  • a composition can be in a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a composition, in particular a pharmaceutical composition, comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, that provides beneficial effects in the treatment of a disease disclosed herein, in particular a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence.
  • the invention provides a combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, that provides beneficial effects in the treatment of conditions for which either a cyclohexanehexol, especially a scyllo-inositol compound, or a secretase inhibitor, especially a beta-secretase inhibitor, have been demonstrated to have a therapeutic effect, including but not limited to Alzheimer's disease, and similar diseases.
  • a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in a composition or combination of the invention may be in a ratio selected to augment the activity of the cyclohexanehexol, especially a scyllo-inositol compound, and/or a secretase inhibitor, especially beta-secretase inhibitor, to provide a beneficial effect.
  • Combinations of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in compositions of the invention may be selected to provide unexpectedly additive effects or greater than additive effects i.e. synergistic effects.
  • the invention provides a pharmaceutical composition comprising a cyclohexanehexol and a secretase inhibitor in combination with a pharmaceutically acceptable carrier, excipient or vehicle, wherein the amounts of cyclohexanehexol and secretase inhibitor are selected to provide an additive or synergistic beneficial effect in preventing or treating a disease disclosed herein.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a cyclohexanehexol and a secretase inhibitor in combination with a pharmaceutically acceptable carrier, excipient or vehicle, wherein the amounts of cyclohexanehexol and secretase inhibitor are selected to provide a beneficial effect in preventing or reducing aggregation of A ⁇ , maintaining synaptic function, and/or reducing A ⁇ load, as a combined preparation for simultaneous, separate or sequential use in treatment of neurodegenerative diseases including Alzheimer's disease and similar diseases.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a cyclohexanehexol and a secretase inhibitor in combination with a pharmaceutically acceptable carrier, excipient or vehicle, wherein the amounts of cyclohexanehexol and secretase inhibitor are selected to provide an additive effect in preventing or reducing aggregation of A ⁇ , maintaining synaptic function, and/or reducing A ⁇ load, as a combined preparation for simultaneous, separate or sequential use in treatment of neurodegenerative diseases including Alzheimer's disease and similar diseases.
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a cyclohexanehexol and a secretase inhibitor in combination with a pharmaceutically acceptable carrier, excipient or vehicle, wherein the amounts of cyclohexanehexol and secretase inhibitor are selected to provide a synergistic effect in preventing or reducing aggregation of A ⁇ , maintaining synaptic function, and/or reducing A ⁇ load, as a combined preparation for simultaneous, separate or sequential use in treatment of neurodegenerative diseases including Alzheimer's disease and similar diseases.
  • the invention provides a pharmaceutical composition comprising an amount of a cyclohexanehexol and an amount of a secretase inhibitor wherein said composition achieves a synergistic effect for treating a neurodegenerative disease in a mammal in need thereof.
  • the invention also provides a pharmaceutical composition in separate containers and intended for simultaneous or sequential administration to a subject especially to provide beneficial effects, comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, both optionally together with pharmaceutically acceptable carriers, excipients, or vehicles.
  • the invention provides a conjugate comprising a cyclohexanehexol, especially a scyllo-inositol compound, interacting with or linked to a secretase inhibitor, especially a beta- secretase inhibitor.
  • a conjugate can provide the beneficial effects described herein.
  • the invention also provides methods for preparing compositions and conjugates of the invention that result in compositions and conjugates with beneficial effects.
  • the invention provides a method of preparing a pharmaceutical composition
  • a pharmaceutical composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially beta-secretase inhibitor, in particular adapted to provide beneficial effects, in particular sustained beneficial effects, following treatment.
  • a method can comprise mixing one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle, in particular, a pharmaceutically acceptable carrier, excipient, or vehicle effective to physically stabilize the cyclohexanehexol compound(s) and one or more secretase inhibitor.
  • a pharmaceutically acceptable carrier, excipient, or vehicle in particular, a pharmaceutically acceptable carrier, excipient, or vehicle effective to physically stabilize the cyclohexanehexol compound(s) and one or more secretase inhibitor.
  • the invention provides a method of preparing a stable pharmaceutical composition of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, adapted to provide beneficial effects following treatment, comprising preparing a composition comprising the cyclohexanehexol, a secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle effective to physically stabilize the cyclohexanehexol and secretase inhibitor.
  • the invention also contemplates the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, composition, conjugate, or combination treatment of the invention for preventing, and/or ameliorating disease severity, disease symptoms, and/or periodicity of recurrence of a condition and/or disease disclosed herein.
  • the invention relates to the use of one or more cyclohexanehexol and a secretase inhibitor as a medicament.
  • the medicament may be suitable for use in treating a disease disclosed herein or is suitable for use in patients who are at risk of developing a disease disclosed herein.
  • the invention also relates to the prevention and treatment, in a subject, of diseases using a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, composition, combination treatment, and/or conjugate of the invention.
  • the invention provides a method for treating and/or preventing a disease in a subject comprising administering to the subject a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially beta-secretase inhibitor, in particular to provide beneficial effects.
  • the invention provides a treatment which results in sustained beneficial effects following treatment.
  • the invention provides a method of treating a disease disclosed herein, in particular a neurodegenerative disease in a subject in need thereof comprising the step of administering to the subject a therapeutically effective amount of a synergistic composition of a cyclohexanehexol and a secretase inhibitor.
  • the invention provides a method for the prevention and/or intervention of a disease disclosed herein in a subject comprising administration of at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially a beta-secretase inhibitor, or a composition or conjugate of the invention to the subject.
  • the invention provides a method of treating a disease comprising administering at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially a beta-secretase inhibitor, a composition, combination treatment or conjugate of the invention to a subject in need thereof to thereby produce beneficial effects.
  • the compounds, composition, and/or conjugate are administered orally or systemically.
  • the invention provides a method for the prevention and/or intervention of a disease discussed herein in a subject comprising administration of at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention to a subject in need thereof to provide beneficial effects.
  • the invention provides a method for the prevention and/or intervention of a disease discussed herein in a subject comprising co-administering at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention to a subject in need thereof.
  • the invention provides a method for amelioriating progression of a disease or obtaining a less severe stage of a disease in a subject suffering from such disease (e.g. Alzheimer's disease) comprising administering a therapeutically effective amount of at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention.
  • a disease e.g. Alzheimer's disease
  • the invention relates to a method of delaying the progression of a disease (e.g. Alzheimer ' s disease) comprising administering a therapeutically effective amount at least one cyclohexanehexol, especially a scyllo-inositol compound and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention.
  • a disease e.g. Alzheimer ' s disease
  • a disease e.g. Alzheimer ' s disease
  • administering a therapeutically effective amount at least one cyclohexanehexol, especially a scyllo-inositol compound and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention.
  • the invention also relates to a method of increasing survival of a subject suffering from a disease comprising administering a therapeutically effective amount of at least one cyclohexanehexol, especially a scyllo-inositol compound and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention.
  • the invention relates to a method of improving the lifespan of a subject suffering from a disease (e.g., Alzheimer's disease) comprising administering a therapeutically effective amount of at least one cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition of the invention.
  • a disease e.g., Alzheimer's disease
  • the invention provides a therapeutic method which comprises identifying a patient diagnosed with a neurodegenerative disorder (such as Alzheimer's disease or MCI) and treating the patient with an effective amount of one or more cyclohexanehexol and one or more secretase inhibitor.
  • An aspect of the invention provides a method for treating a neurodegenerative disorder.
  • a therapeutically effective amount of one or more cyclohexanehexol and secretase inhibitor is administered to an individual in need of such treatment.
  • An individual in need of such treatment may have a neurodegenerative disorder, a predisposition to a neurodegenerative disorder, and/or desire prophylaxis against or a delay in such disorders.
  • a neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, dementia, mild cognitive impairment, and tauopathies (e.g. corticobasal degeneration, frontotemporal dementia with Parkinsonism linked to chromosome 17, and progressive supranuclear palsy).
  • the invention has particular applications in preventing and/or treating Alzheimer's disease and other similar diseases.
  • the invention provides a method for preventing and/or treating Alzheimer's disease comprising administering a therapeutically effective amount of a cyclohexanehexol, especially a scyllo-inositol compound, and at least one secretase inhibitor, especially beta-secretase inhibitor, or a composition or conjugate of the invention.
  • the invention relates to a method of treating Alzheimer's disease comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor, which upon administration to a subject with symptoms of Alzheimer's disease produces beneficial effects, in particular sustained beneficial effects.
  • the invention provides a method of treating Alzheimer's disease comprising administering one or more cyclohexanehexol and one or more secretase inhibitor in effective amounts for reducing at least one symptom of Alzheimer's disease or for reducing, preventing an increase (or slowing the rate of increase) in or delaying the onset of, at least one symptom of Alzheimer's disease.
  • An embodiment of the invention provides a method for preventing and/or treating
  • Alzheimer's disease the method comprising administering to a mammal in need thereof a combination of a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor especially a beta-secretase inhibitor in an amount sufficient to inhibit, reduce, or reverse A ⁇ fibril assembly or aggregation, A ⁇ toxicity, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils thereby preventing and/or treating the disease.
  • a cyclohexanehexol especially a scyllo-inositol compound
  • a secretase inhibitor especially a beta-secretase inhibitor in an amount sufficient to inhibit, reduce, or reverse A ⁇ fibril assembly or aggregation, A ⁇ toxicity, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence,
  • the invention provides methods for treating Alzheimer's disease in a patient in need thereof by administering a composition comprising a cyclohexanehexol, especially a scyllo- inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor, composition, or conjugate of the invention in an amount sufficient to inhibit, reduce, or reverse A ⁇ fibril assembly or aggregation, A ⁇ toxicity, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils in the subject.
  • the invention provides a method of reversing amyloid deposition and neuropathology after the onset of cognitive deficits and amyloid plaque neuropathology in a subject comprising administering to the subject a therapeutically effective amount of a composition of the invention.
  • the invention also contemplates the use of a composition comprising at least one cyclohexanehexol, especially a scyllo-inositol compound and at least one secretase inhibitor, especially a beta-secretase inhibitor, for the preparation of a medicament for preventing and/or treating a disease.
  • the invention relates to the use of synergistically effective amounts of at least one cyclohexanehexol, especially a scyllo-inositol compound and at least one secretase inhibitor, especially beta-secretase inhibitor, for the preparation of a medicament for preventing and/or treating a condition or disease.
  • the invention additionally provides uses of a pharmaceutical composition and a conjugate of the invention in the preparation of medicaments for the prevention and/or treatment of diseases disclosed herein.
  • the medicaments provide beneficial effects, preferably sustained beneficial effects following treatment.
  • the present invention in part relates to a method of treatment comprising a combination of active agents which may be administered separately or as conjugates, the invention also provides a kit comprising a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor, a pharmaceutical composition, or conjugate of the invention in kit form.
  • the invention provides a kit comprising one or more cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor, or a pharmaceutical composition of the invention.
  • the invention provides a kit for preventing and/or treating a disease, containing a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, a secretase inhibitor, especially a beta-secretase inhibitor, a container, and instructions for use.
  • the composition of the kit can further comprise a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a kit for preventing and/or treating Alzheimer's disease and similar diseases, containing a composition comprising a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, a container, and instructions for use.
  • the composition of the kit can further comprise a pharmaceutically acceptable carrier.
  • treating refers to reversing, alleviating, or inhibiting the progress of a disease, or one or more symptoms of such disease, to which such term applies.
  • the term also refers to preventing a disease, and includes preventing the onset, or preventing the symptoms associated with a disease.
  • a treatment may be either performed in an acute or chronic way.
  • the term also refers to reducing the severity of a disease or symptoms associated with such disease prior to affliction with the disease.
  • Such prevention or reduction of the severity of a disease prior to affliction refers to administration of a compound or composition of the present invention to a subject that is not at the time of administration afflicted with the disease.
  • Preventing also refers to preventing the recurrence of a disease, or of one or more symptoms associated with such disease.
  • treatment and “therapeutically,” refer to the act of treating, as “treating” is defined above.
  • the purpose of prevention and intervention is to combat the disease, condition, or disorder and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications, or alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
  • administering or “administration” refers to the process by which cyclohexanehexols and/or secretase inhibitors, compositions, and/or conjugates disclosed herein are delivered to a subject for treatment or prophylactic purposes.
  • Cyclohexanehexols and/or secretase inhibitors, compositions, and/or conjugates are administered in accordance with good medical practices taking into account the subject's clinical condition, the site and method of administration, dosage, subject age, sex, body weight, and other factors known to the physician.
  • a “combination treatment” and “administering in combination” mean that the active ingredients are administered concurrently to a patient being treated.
  • each component may be administered at the same time, or sequentially in any order at different points in time. Therefore, each component may be administered separately, but sufficiently close in time to provide the desired effect, in particular a beneficial, additive, or synergistic effect.
  • the first compound may be administered in a regimen that additionally comprises treatment with the second compound.
  • the terms refer to the administration of a cyclohexanehexol and a secretase inhibitor, including separate administration of medicaments each containing one of the compounds as well as simultaneous administration whether or not the compounds are combined in one formulation or whether they are in separate formulations.
  • an “additive effect” of a cyclohexanehexol and a secretase inhibitor, especially beta- secretase inhibitor refers to an effect that is equal to the sum of the effects of the two individual compounds.
  • a “synergistic effect” of a cyclohexanehexol and a secretase inhibitor, especially a beta-secretase inhibitor refers to an effect that is greater than the additive effect that results from the sum of the effects of the two individual compounds.
  • association refers to any physical association between molecules.
  • the terms preferably refer to a stable association between two molecules due to, for example, electrostatic, hydrophobic, ionic, hydrogen-bond interactions, or covalent interactions.
  • a “beneficial effect” refers to an effect of a cyclohexanehexol and secretase inhibitor or composition thereof in certain aspects of the invention, including favorable or enhanced pharmacological and/or therapeutic effects, and/or improved biological activity.
  • the beneficial effects include without limitation prevention, reduction, reversal or inhibition of A ⁇ fibril assembly or aggregation, A ⁇ toxicity, A ⁇ 42 levels, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils.
  • the beneficial effects include but are not limited to one or more of the following: disruption of aggregated A ⁇ or A ⁇ oligomers; increased or restored long term potentiation; maintenance of synaptic function; inhibition, reduction or reversal of A ⁇ -induced progressive cognitive decline and cerebral amyloid plaque pathology; improved cognition; increased lifespan; reduced cerebral accumulation of A ⁇ ; reduced deposition of cerebral amyloid plaques; reduced soluble A ⁇ oligomers (e.g. A ⁇ 42) in the brain; reduced glial activity; reduced inflammation; and/or cognitive decline.
  • a beneficial effect is a favourable characteristic of a composition/formulation of the invention and includes enhanced stability, a longer half life, and/or enhanced uptake and transport across the blood brain barrier.
  • the beneficial effect is a "sustained beneficial effect" where the beneficial effect is sustained for a prolonged period of time after termination of treatment.
  • a treatment can be sustained over several years thereby having a major beneficial impact on the severity of the disease and its complications
  • a beneficial effect may be sustained for a prolonged period of at least about 2 to 4 weeks, 2 to 5 weeks, 3 to 5 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 10 weeks, 2 to 12 weeks, 2 to 14 weeks, 2 to 16 weeks, 2 to 20 weeks, 2 to 24 weeks, 2 weeks to 12 months, 2 weeks to 18 months, 2 weeks to 24 months, or several years following treatment.
  • the period of time a beneficial effect is sustained may correlate with the duration and timing of the treatment.
  • a subject may be treated continuously for about or at least about 2 to 4 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 10 weeks, 2 to 12 weeks, 2 to 14 weeks, 2 to 16 weeks, 2 weeks to 6 months, 2 weeks to 12 months, 2 weeks to 18 months, or several years, periodically or continuously.
  • the beneficial effect may be a statistically significant effect in terms of statistical analysis of an effect of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, versus the effects without the compounds or with the individual compounds.
  • "Statistically significant" or “significantly different” effects or levels may represent levels that are higher or lower than a standard. In embodiments of the invention, the difference may be 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 40, or 50 times higher or lower compared with the effect obtained without a cyclohexanehexol and/or secretase inhibitor.
  • subject refers to an animal including a warm- blooded animal such as a mammal, which is afflicted with or suspected of having or being pre-disposed to a disease disclosed herein.
  • Mammal includes without limitation any members of the Mammalia. In general, the terms refer to a human.
  • the terms also include domestic animals bred for food or as pets, including horses, cows, sheep, poultry, fish, pigs, cats, dogs, and zoo animals, goats, apes (e.g. gorilla or chimpanzee), and rodents such as rats and mice.
  • Typical subjects for treatment include persons susceptible to, suffering from or that have suffered a disease disclosed herein.
  • a subject show signs of cognitive deficits and amyloid plaque neuropathology.
  • the subjects are suspectible to, or suffer from Alzheimer's disease.
  • the subject is in the late presymptomatic phase of Alzheimer's disease prior to the onset of overt cognitive deficits and amyloid neuropathology.
  • pharmaceutically acceptable carrier, excipient, or vehicle refers to a medium which does not interfere with the effectiveness or activity of an active ingredient and which is not toxic to the hosts to which it is administered.
  • a carrier, excipient, or vehicle includes diluents, binders, adhesives, lubricants, disintegrates, bulking agents, wetting or emulsifying agents, pH buffering agents, and miscellaneous materials such as absorbants that may be needed in order to prepare a particular composition.
  • Examples of carriers, excipients, and vehicles include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The use of such media and agents for an active substance is well known in the art.
  • Acceptable carriers, excipients or vehicles may be selected from any of those commercially used in the art, in particular, those used in pharmaceutical compositions of secretase inhibitors and cyclohexanehexols.
  • “Therapeutically effective amount” relates to the amount or dose of active compounds or a composition of the invention that will lead to one or more desired beneficial effects, including enhanced therapeutic effects, in particular, one or more sustained beneficial effects.
  • a therapeutically effective amount of a substance can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the substance to elicit a desired response in the individual.
  • a dosage regimen may be adjusted to provide the optimum therapeutic response (e.g. sustained beneficial effects). For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • Suboptimal dose or suboptimal dosage refers to a dose or dosage of an active compound which is less than the optimal dose or dosage for that compound when used in monotherapy.
  • cyclohexanehexol is understood to refer to any compound, which fully or partially, directly or indirectly, provides one or more beneficial effects described herein and includes a compound of the formula I, II, III, IV, V or VI described herein, or an analog or derivative (e.g. functional derivative, chemical derivative or variant), salt, prodrug, polymorph, crystalline form, solvate or hydrate thereof.
  • the cyclohexanehexol is an inositol.
  • a cyclohexanehexol includes a pharmaceutically acceptable salt.
  • “Pharmaceutically acceptable salt(s),” means a salt that is pharmaceutically acceptable and has the desired pharmacokinetic properties.
  • pharmaceutically acceptable salts is meant those salts which are suitable for use in contact with the tissues of a subject or patient without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are described for example, in S. M. Berge, et al., J. Pharmaceutical Sciences, 1977, 66:1. Suitable salts include salts that may be formed where acidic protons in the compounds are capable of reacting with inorganic or organic bases.
  • Suitable inorganic salts include those formed with alkali metals, e.g. sodium and potassium, magnesium, calcium, and aluminum.
  • Suitable organic salts include those formed with organic bases such as the amine bases, e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • Suitable salts also include acid addition salts formed with inorganic acids (e.g. hydrochloride and hydrobromic acids) and organic acids (e.g. acetic acid, citric acid, maleic acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benezenesulfonic acid).
  • a pharmaceutically acceptable salt may be a mono-acid-mono-salt or a di-salt; and similarly where there are more than two acidic groups present, some or all of such groups can be salified.
  • a cyclohexanehexol includes a functional derivative, a chemical derivative, or variant.
  • a "functional derivative refers to a compound that possesses an activity (either functional or structural) that is substantially similar to the activity of a cyclohexanehexol disclosed herein.
  • the term “chemical derivative” describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule.
  • variant is meant to refer to a molecule substantially similar in structure and function to a cyclohexanehexol or a part thereof.
  • a molecule is "substantially similar” to a cyclohexanehexol if both molecules have substantially similar structures or if both molecules possess similar biological activity.
  • analog includes a molecule substantially similar in function to a cyclohexanehexol.
  • An “analog” can include a chemical compound that is structurally similar to another but differs slightly in composition. Differences include without limitation the replacement of an atom or functional group with an atom or functional group of a different element. Analogs and derivatives may be identified using computational methods with commercially available computer modeling programs.
  • a cyclohexanehexol includes crystalline forms which may exist as polymorphs. Solvates of the compounds formed with water or common organic solvents are also intended to be encompassed within the term. In addition, hydrate forms of the compounds and their salts are encompassed within this invention. Futher prodrugs of compounds of cyclohexanehexols are encompassed within the term.
  • solvate means a physical association of a compound with one or more solvent molecules or a complex of variable stoichiometry formed by a solute (for example, a cyclohexanehexol disclosed herein) and a solvent, for example, water, ethanol, or acetic acid.
  • a solute for example, a cyclohexanehexol disclosed herein
  • a solvent for example, water, ethanol, or acetic acid.
  • This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding.
  • the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • the solvents selected do not interfere with the biological activity of the solute.
  • Solvates encompass both solution-phase and isolatable solvates.
  • solvates include hydrates, ethanolates, methanolates, and the like. Dehydrate, co-crystals, anhydrous, or amorphous forms of the cyclohexanhexol compounds are also contemplated herein.
  • hydrate means a solvate wherein the solvent molecule(s) is/are H 2 O, including, mono-, di-, and various poly-hydrates thereof. Solvates can be formed using various methods known in the art.
  • Crystalline compounds of a cyclohexanehexol disclosed herein can be in the form of a free base, a salt, or a co-crystal.
  • Free base compounds can be crystallized in the presence of an appropriate solvent in order to form a solvate.
  • Acid salt compounds of cyclohexanehexols e.g. HCl, HBr, benzoic acid
  • solvates can be formed by the use of acetic acid or ethyl acetate.
  • the solvate molecules can form crystal structures via hydrogen bonding, van der Waals forces, or dispersion forces, or a combination of any two or all three forces.
  • the amount of solvent used to make solvates can be determined by routine testing. For example, a monohydrate of a cyclohexanehexol would have about 1 equivalent of solvent (H 2 O) for each equivalent of a cyclohexanehexol. However, more or less solvent may be used depending on the choice of solvate desired. Cyclohexanehexols for use in the present invention may be amorphous or may have different crystalline polymorphs, possibly existing in different solvation or hydration states. By varying the form of a drug, it is possible to vary the physical properties thereof.
  • crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph.
  • Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapor pressure, density, color, and compressibility.
  • prodrug means a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s).
  • prodrugs have metabolically cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds.
  • the prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity).
  • prodrugs themselves have weak or no biological activity and are stable under ordinary conditions.
  • Prodrugs can be readily prepared from the parent compounds using methods known in the art, such as those described, for example, in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991 , particularly Chapter 5 : "Design and Applications of Prodrugs”; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985, particularly pp.
  • prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g. N,N-dimethylaminocarbonyl) of hydroxy functional groups on compounds of the present invention, and the like.
  • esters e.g., acetate, formate, and benzoate derivatives
  • carbamates e.g. N,N-dimethylaminocarbonyl
  • a cyclohexanehexol includes a compound with the base structure of the formula I, in particular a substantially pure, compound of the formula I.
  • X is a cyclohexane, in particular a myo-, scyllo, epi-, chiro, or allo-inositol radical, wherein one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are independently hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkynyl, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thi
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl.
  • a cyclohexanehexol of the formula I is used wherein X is a radical of scyllo-inositol or epi-inositol.
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, or one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfinyl, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyanato, halo, seleno
  • the cyclohexanehexol is a substantially pure, compound of the formula I or II as defined herein with the proviso that when (a) one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl or fluorine no more than four of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, (b) one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is amino or azide no more than four of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, (c) two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are amino, no more than three of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, and (d
  • X is a cyclohexane ring
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, or at least one of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is independently selected from hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1- QaIkOXy, C 2 -C 6 alkenyloxy, C 3 -Ci 0 cycloalkyl, C 4 -C 10 cycloalkenyl, C 3 -C 10 cycloalkoxy, C 6 -C 10 aryl, C 6 -C 10 aryloxy, C ⁇ -Cioaryl-Q-Csalkoxy, C 6 -C 10 aroyl, C 6 -Cioheteroaryl, C 3 -Ci 0 heterocyclic,
  • the cyclohexanehexol is a substantially pure, compound of the formula IV, Formula IV wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are defined as for formula III, or a pharmaceutically acceptable salt thereof.
  • radicals including "alkyl”, “alkoxy”, “alkenyl”, “alkynyl”, “hydroxyl” etc, refer to both unsubstituted and substituted radicals.
  • substituted means that any one or more moiety on a designated atom (e.g., hydroxyl) is replaced with a selected group provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or radicals are permissible only if such combinations result in stable compounds.
  • “Stable compound” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • Alkyl either alone or within other terms such as “arylalkyl” means a monovalent, saturated hydrocarbon radical which may be a straight chain (i.e., linear) or a branched chain.
  • an alkyl radical comprises from about 1 to 24 or 1 to 20 carbon atoms, preferably from about 1 to 10, 1 to 8, 3 to 8, 1 to 6, or 1 to 3 carbon atoms.
  • alkyl radicals include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, isopentyl, amyl, sec-butyl, tert-butyl, tert-pentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, n-dodecyl, n-tetradecyl, pentadecyl, n-hexadecyl, heptadecyl, n-octadecyl, nonadecyl, eicosyl, dosyl, n-tetracosyl, and the like, along with branched variations thereof.
  • an alkyl radical is a C]-C 6 lower alkyl comprising or selected from the group consisting of methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, isopentyl, amyl, tributyl, sec-butyl, tert-butyl, tert-pentyl, and n-hexyl.
  • An alkyl radical may be optionally substituted with substituents at positions that do not significantly interfere with the preparation of the cyclohexanehexols and do not significantly reduce the efficacy of the compounds.
  • an alkyl radical may be optionally substituted.
  • an alkyl radical is substituted with one to five substituents including halo, lower alkoxy, haloalkoxy, alkylalkoxy, haloalkoxyalkyl, hydroxyl, cyano, nitro, thio, amino, substituted amino, carboxyl, sulfonyl, sulfenyl, sulfinyl, sulfate, sulfoxide, substituted carboxyl, halogenated lower alkyl (e.g.
  • CF 3 halogenated lower alkoxy, hydroxycarbonyl, lower alkoxycarbonyl, lower alkylcarbonyloxy, lower alkylcarbonylamino, aryl (e.g., phenylmethyl (i.e. benzyl)), heteroaryl (e.g., pyridyl), and heterocyclic (e.g., piperidinyl, morpholinyl).
  • aryl e.g., phenylmethyl (i.e. benzyl)
  • heteroaryl e.g., pyridyl
  • heterocyclic e.g., piperidinyl, morpholinyl
  • substituted alkyl refers to an alkyl group substituted by, for example, one to five substituents, and preferably 1 to 3 substituents, such as alkyl, alkoxy, oxo, alkanoyl, aryl, aralkyl, aryloxy, alkanoyloxy, cycloalkyl, acyl, amino, hydroxyamino, alkylamino, arylamino, alkoxyamino, aralkylamino, cyano, halogen, hydroxyl, carboxyl, carbamyl, carboxylalkyl, keto, thioketo, thiol, alkylthiol, arylthio, aralkylthio, sulfonamide, thioalkoxy, and nitro.
  • substituents such as alkyl, alkoxy, oxo, alkanoyl, aryl, aralkyl, aryloxy, alkanoyloxy,
  • alkenyl refers to an unsaturated, acyclic branched or straight-chain hydrocarbon radical comprising at least one double bond.
  • Alkenyl radicals may contain from about 2 to 24 or 2 to 10 carbon atoms, preferably from about 3 to 8 carbon atoms and more preferably about 3 to 6 or 2 to 6 carbon atoms.
  • alkenyl radicals include ethenyl, propenyl such as prop- 1 -en- 1 -yl, prop- 1 -en-2-yl, prop-2-en- 1 -yl (allyl), prop-2-en-2- yl, buten-1-yl, but- 1 -en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-1,3- dien-1-yl, buta-l,3-dien-2-yl, hexen-1-yl, 3-hydroxyhexen-l-yl, hepten-1-yl, and octen-1-yl, and the like.
  • propenyl such as prop- 1 -en- 1 -yl, prop- 1 -en-2-yl, prop-2-en- 1 -yl (allyl), prop-2-en-2- yl, buten-1-yl, but-
  • An alkenyl radical may be optionally substituted similar to alkyl.
  • substituted alkenyl refers to an alkenyl group substituted by, for example, one to three substituents, preferably one to two substituents, such as alkyl, alkoxy, haloalkoxy, alkylalkoxy, haloalkoxy alkyl, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, amino, alkylamino, alkanoylamino, aminoacyl, aminoacyloxy, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, carbamyl, keto, thioketo, thiol, alkylthio, sulfonyl, sulfonamido, thioalkoxy, aryl, nitro, and the like.
  • alkynyl refers to an unsaturated, branched or straight-chain hydrocarbon radical comprising one or more triple bonds.
  • Alkynyl radicals may contain about 1 to 20, 1 to 15, or 2- 10 carbon atoms, preferably about 3 to 8 carbon atoms and more preferably about 3 to 6 carbon atoms.
  • alkynyl refers to straight or branched chain hydrocarbon groups of 2 to 6 carbon atoms having one to four triple bonds.
  • alkynyl radicals examples include ethynyl, propynyls, such as prop-1-yn-l-yl, prop-2-yn-l-yl, butynyls such as but-1-yn-l-yl, but-l-yn-3-yl, and but-3-yn-l-yl, pentynyls such as pentyn-1-yl, pentyn-2-yl, and 4-methoxypentyn-2-yl, and 3-methylbutyn- 1 -yl, hexynyls such as hexyn- 1 -yl, hexyn-2- yl, and hexyn-3-yl, and 3,3-dimethylbutyn-l-yl radicals and the like.
  • This radical may be optionally substituted similar to alkyl.
  • cycloalkynyl refers to cyclic alkynyl groups.
  • substituted alkynyl refers to an alkynyl group substituted by, for example, a substituent, such as, alkyl, alkoxy, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, amino, alkylamino, alkanoylamino, aminoacyl, aminoacyloxy, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, carbamyl, keto, thioketo, thiol, alkylthio, sulfonyl, sulfonamido, thioalkoxy, aryl, nitro, and the like.
  • a substituent such as, alkyl, alkoxy, alkanoyl, alkanoyloxy, cycloalkyl, cycloalkoxy, acyl, acylamino, acyloxy, amino, alkylamin
  • alkylene refers to a linear or branched radical having from about 1 to 10, 1 to 8, 1 to 6, or 2 to 6 carbon atoms and having attachment points for two or more covalent bonds. Examples of such radicals are methylene, ethylene, ethylidene, methylethylene, and isopropylidene.
  • alkenylene refers to a linear or branched radical having from about 2 to 10, 2 to 8 or 2 to 6 carbon atoms, at least one double bond, and having attachment points for two or more covalent bonds.
  • halogen or halo refers to fluoro, chloro, bromo and iodo, especially fluoro or chloro.
  • hydroxyl or "hydroxy” refers to a single -OH group.
  • cyano refers to a carbon radical having three of four covalent bonds shared by a nitrogen atom, in particular -CN.
  • alkoxy refers to a linear or branched oxy-containing radical having an alkyl portion of one to about ten carbon atoms, which may be substituted. Particular alkoxy radicals are "lower alkoxy" radicals having about 1 to 6, 1 to 4 or 1 to 3 carbon atoms. An alkoxy having about 1-6 carbon atoms includes a C 1 -C 6 alkyl-O- radical wherein C 1 -C 6 alkyl has the meaning set out herein. Illustrative examples of alkoxy radicals include without limitation methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy.
  • alkoxy radical may optionally be further substituted with one or more substitutents disclosed herein including alkyl atoms (in particular lower alkyl) to provide “alkylalkoxy” radicals; halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy” radicals (e.g. fiuoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy) and "haloalkoxyalkyl” radicals (e.g. fluoromethoxymethyl, chloromethoxyethyl, trifluoromethoxymethyl, difluoromethoxyethyl, and trifluoroethoxymethyl).
  • alkyl atoms in particular lower alkyl
  • halo atoms such as fluoro, chloro or bromo, to
  • acyl alone or in combination, means a carbonyl or thiocarbonyl group bonded to a radical selected from, for example, optionally substituted, hydrido, alkyl (e.g. haloalkyl), alkenyl, alkynyl, alkoxy ("acyloxy” including acetyloxy, butyryloxy, iso-valeryloxy, phenylacetyloxy, benzoyloxy, p-methoxybenzoyloxy, and substituted acyloxy such as alkoxyalkyl and haloalkoxy), aryl, halo, heterocyclyl, heteroaryl, sulfinyl (e.g.
  • alkylsulfinylalkyl sulfonyl (e.g. alkylsulfonylalkyl), cycloalkyl, cycloalkenyl, thioalkyl, thioaryl, amino (e.g., alkylamino or dialkylamino), and aralkoxy.
  • acyl radicals are formyl, acetyl, 2-chloroacetyl, 2-bromacetyl, benzoyl, trifluoroacetyl, phthaloyl, malonyl, nicotinyl, and the like.
  • acyl refers to a group -C(O)R 9 , where R 9 is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl.
  • R 9 is hydrogen, alkyl, cycloalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl.
  • examples include, but are not limited to formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, benzylcarbonyl and the like.
  • cycloalkyl refers to radicals having from about 3 to 16 or 3 to 15 carbon atoms and containing one, two, three, or four rings wherein such rings may be attached in a pendant manner or may be fused.
  • cycloalkyl refers to an optionally substituted, saturated hydrocarbon ring system containing 1 to 2 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C 3 -C 7 carbocylic ring.
  • cycloalkyl groups include single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclododecyl, and the like, or multiple ring structures such as adamantanyl, and the like.
  • the cycloalkyl radicals are "lower cycloalkyl” radicals having from about 3 to 10, 3 to 8, 3 to 6, or 3 to 4 carbon atoms, in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the term "cycloalkyl” also embraces radicals where cycloalkyl radicals are fused with aryl radicals or heterocyclyl radicals. A cycloalkyl radical may be optionally substituted.
  • substituted cycloalkyl refers to cycloalkyl groups having from 1 to 5 (in particular 1 to 3) substituents including without limitation alkyl, alkenyl, alkoxy, cycloalkyl, substituted cycloalkyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyacylamino, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, keto, thioketo, thiol, thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, hydroxyamino, alkoxyamino, and nitro.
  • cycloalkenyl refers to radicals comprising about 2 to 16, 4 to 16, 2 to 15, 2 to 10, 4 to 10, 3 to 8, 3 to 6, or 4 to 6 carbon atoms, one or more carbon-carbon double bonds, and one, two, three, or four rings wherein such rings may be attached in a pendant manner or may be fused.
  • the cycloalkenyl radicals are "lower cycloalkenyl” radicals having three to seven carbon atoms, in particular cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.
  • a cycloalkenyl radical may be optionally substituted with groups as disclosed herein.
  • cycloalkoxy refers to cycloalkyl radicals (in particular, cycloalkyl radicals having 3 to 15, 3 to 8 or 3 to 6 carbon atoms) attached to an oxy radical.
  • examples of cycloalkoxy radicals include cyclohexoxy and cyclopentoxy.
  • a cycloalkoxy radical may be optionally substituted with groups as disclosed herein.
  • aryl alone or in combination, refers to a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendant manner or may be fused.
  • fused means that a second ring is present (i.e, attached or formed) by having two adjacent atoms in common or shared with the first ring.
  • an aryl radical comprises 4 to 24 carbon atoms, in particular 4 to 10, 4 to 8, or 4 to 6 carbon atoms.
  • aryl includes without limitation aromatic radicals such as phenyl, naphthyl, indenyl, benzocyclooctenyl, benzocycloheptenyl, pentalenyl, azulenyl, tetrahydronaphthyl, indanyl, biphenyl, diphenyl, acephthylenyl, fluorenyl, phenalenyl, phenanthrenyl, and anthracenyl, preferably phenyl.
  • An aryl radical may be optionally subsitituted (i.e., "substituted aryl") with, for example, one to four substituents such as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, alkanoyl, alkanoyloxy, aryloxy, aralkyloxy, amino, alkylamino, arylamino, aralkylamino, dialkylamino, alkanoylamino, thiol, alkylthio, ureido, nitro, cyano, carboxy, carboxyalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, arylsulfonylamine, sul
  • a substituent may be further substituted by hydroxy, halo, alkyl, alkoxy, alkenyl, alkynyl, aryl or aralkyl.
  • an aryl radical is substituted with hydroxyl, alkyl, carbonyl, carboxyl, thiol, amino, and/or halo.
  • aralkyl refers to an aryl or a substituted aryl group bonded directly through an alkyl group, such as benzyl.
  • substituted aryl radicals include chlorobenyzl, and amino benzyl.
  • aryloxy refers to aryl radicals, as defined above, attached to an oxygen atom.
  • exemplary aryloxy groups include napthyloxy, quinolyloxy , isoquinolizinyloxy , and the like.
  • arylalkoxy refers to an aryl group attached to an alkoxy group. Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-naphth-2-ylpropoxy, and 5-phenylpentyloxy.
  • aroyl refers to aryl radicals, as defined above, attached to a carbonyl radical as defined herein, including without limitation benzoyl and toluoyl. An aroyl radical may be optionally substituted with groups as disclosed herein.
  • heteroaryl refers to fully unsaturated heteroatom-containing ring-shaped aromatic radicals having from 3 to 15, 3 to 10, 5 to 15, 5 to 10, or 5 to 8 ring members selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom.
  • a heteroaryl radical may contain one, two or three rings and the rings may be attached in a pendant manner or may be fused.
  • heteroaryl radicals include without limitation, an unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, in particular, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl and the like; an unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, in particular, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl and the like; an unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, in particular, 2-furyl
  • heterocyclic radicals are fused with aryl radicals, in particular bicyclic radicals such as benzofuran, benzothiophene, and the like.
  • a heteroaryl radical may be optionally substituted with groups as disclosed herein.
  • heterocyclic refers to saturated and partially saturated heteroatom- containing ring-shaped radicals having from about 3 to 15, 3 to 10, 5 to 15, 5 to 10, or 3 to 8 ring members selected from carbon, nitrogen, sulfur and oxygen, wherein at least one ring atom is a heteroatom.
  • a heterocylic radical may contain one, two or three rings wherein such rings may be attached in a pendant manner or may be fused.
  • saturated heterocyclic radicals include without limitiation a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl]; a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl]; and, a saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl] etc.
  • a saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, and piperazinyl
  • heterocyclyl radicals examples include without limitation dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole.
  • Illustrative heterocyclic radicals include without limitation 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, 1 ,3-dioxolanyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1 ,4-dioxanyl, morpholinyl, 1 ,4-dithianyl, thiomorpholinyl, and the like.
  • the term "sulfate”, used alone or linked to other terms, is art recognized and includes a group that can be represented by the formula:
  • R 16 is an electron pair, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, carbohydrate, peptide or peptide derivative.
  • sulfonyl used alone or linked to other terms such as alkylsulfonyl or arylsulfonyl, refers to the divalent radicals -SO 2 -.
  • R 1 , R 3 , R 4 , R 5 , or R 6 is a sulfonyl group
  • the sulfonyl group may be attached to a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl, or heterocyclic group, carbohydrate, peptide, or peptide derivative .
  • R 16 is an electron pair, hydrogen, alkyl, cycloalkyl, aryl, alkenyl, alkynyl, cycloalkenyl, cycloalkynyl, heterocyclic, carbohydrate, peptide, or peptide derivative
  • sulfonated alkyl groups include ethyl sulfuric acid, ethanesulfonic acid,
  • 2-aminoethan-l-ol sulfuric acid 1 -propanesulfonic acid, 2-propanesulfonic acid, 1 ,2-diethanedisulfonic acid, 1,2-ethanediol disulfuric acid, 1,3-propanedisulfonic acid, 1-propanol sulfuric acid, 1,3 -propanediol disulfuric acid, 1 -butanesulfonic acid, 1 ,4-butanediol disulfuric acid, 1,2-ethanediol disulfuric acid, 3-amino-l -propanesulfonic acid, 3-hydroxypropanesulfonic acid sulfate, 1 ,4-butanesulfonic acid, 1 ,4-butanediol monosulfuric acid, 1-pentanesulfonic acid, 1,5-pentanedisulfonic acid, 1 ,5-pentanediol sulfuric acid, 4-heptanes
  • cycloalkyl sulfonated groups include 1,3-cyclohexanediol disulfate, and 1, 3, 5-heptanetriol trisulfate.
  • aryl sulfonated groups include 1,3-benzenedisulfonic acid, 2,5-dimethoxy-l,4-benzenedisulfonic acid, 4-amino-3 -hydroxy- 1-naphthalenesulfonic acid, 3, 4-diamino- 1-naphthalenesulfonic acid, and pharmaceutically acceptable salts thereof.
  • heterocyclic sulfonated compounds include
  • sulfonated carbohydrates are sucrose octasulfonate, 5-deoxy-l,2-O- isopropylidene- ⁇ -D-xy lofuranose-5 -sulfonic acid or an alkali earth metal salt thereof, methyl- ⁇ -D-glucopyranoside 2,3-disulfate, methyl 4, -O-benzylidene- ⁇ -D-glucopyranoside 2,
  • -S(O)-alkyl or arylsulfinyl, refers to the divalent radicals -S(O)-.
  • amino alone or in combination, refers to a radical where a nitrogen atom
  • (N) is bonded to three substituents being any combination of hydrogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl or silyl with the general chemical formula -NR 10 R where
  • R 10 and R 11 can be any combination of hydrogen, hydroxyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, silyl, heteroaryl, or heterocyclic which may or may not be substituted.
  • one substituent on the nitrogen atom may be a hydroxyl group (-OH) to provide an amine known as a hydroxylamine.
  • amino groups are amino (-NH 2 ), alkylamino, acylamino, cycloamino, acycloalkylamino, arylamino, arylalkylamino, and lower alkylsilylamino, in particular methylamino, ethylamino, dimethylamino, 2-propylamino, butylamino, isobutylamino, cyclopropylamino, benzylamino, allylamino, hydroxylamino, cyclohexylamino, piperidine, benzylamino, diphenylmethylamino, tritylamino, trimethylsilylamino, and dimethyl-tert.-butylsilylamino.
  • thiol means -SH.
  • sulfenyl refers to the radical -SR 12 wherein R 12 is not hydrogen.
  • R 12 may be alkyl, alkenyl, alkynyl, cycloalkyl, aryl, silyl, heterocyclic, heteroaryl, carbonyl, or carboxyl.
  • thioalkyl refers to a chemical functional group where a sulfur atom (S) is bonded to an alkyl, which may be substituted.
  • thioalkyl groups are thiomethyl, thioethyl, and thiopropyl.
  • thioaryl alone or in combination, refers to a chemical functional group where a sulfur atom (S) is bonded to an aryl group with the general chemical formula -SR 13 where R 13 is an aryl group which may be substituted.
  • thioaryl groups and substituted thioaryl groups are thiophenyl, para-chlorothiophenyl, thiobenzyl, 4-methoxy- thiophenyl, 4-nitro-thiophenyl, and para-nitrothiobenzyl.
  • thioalkoxy refers to a chemical functional group where a sulfur atom (S) is bonded to an alkoxy group with the general chemical formula -SR 15 where R 15 is an alkoxy group which may be substituted.
  • a "thioalkoxy group” has 1 -6 carbon atoms and refers to a -S-(O)-Ci-C 6 alkyl group wherein Ci -C 6 alkyl have the meaning as defined above.
  • Illustrative examples of a straight or branched thioalkoxy group or radical having from 1 to 6 carbon atoms, also known as a Cj -C 6 thioalkoxy include thiomethoxy and thioethoxy.
  • carbonyl refers to a carbon radical having two of the four covalent bonds shared with an oxygen atom.
  • carboxyl refers to -C(O)OR 14 - wherein R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted.
  • the carboxyl groups are in an esterified form and may contain as an esterifying group lower alkyl groups.
  • -C(O)OR 14 provides an ester or an amino acid derivative.
  • An esterified form is also particularly referred to herein as a "carboxylic ester".
  • a "carboxyl” may be substituted, in particular substituted with alkyl which is optionally substituted with one or more of amino, amine, halo, alkylamino, aryl, carboxyl, or a heterocyclic.
  • the carboxyl group is methoxycarbonyl, butoxycarbonyl, tert.alkoxycarbonyl such as tert.butoxycarbonyl, arylmethyoxycarbonyl having one or two aryl radicals including without limitation phenyl optionally substituted by, for example, lower alkyl, lower alkoxy, hydroxyl, halo, and/or nitro, such as benzyloxycarbonyl, methoxybenxyloxycarbonyl, diphenylmethoxycarbonyl, 2-bromoethoxy carbonyl, 2-iodoethoxycarbonyltert.butylcarbonyl, 4-nitrobenzyloxycarbonyl, diphenylmethoxy-carbonyl, benzhydroxycarbonyl, di-(4-methoxyphenyl-methoxycarbonyl, 2-bromoethoxycarbonyl, 2-iodoethoxycarbonyl, 2-trimethylsilylethoxycarbony
  • Additional carboxyl groups in esterified form are silyloxycarbonyl groups including organic silyloxycarbonyl.
  • the silicon substituent in such compounds may be substituted with lower alkyl (e.g. methyl), alkoxy (e.g. methoxy), and/or halo (e.g. chlorine).
  • Examples of silicon substituents include trimethylsilyl and dimethyltert.butylsilyl.
  • carboxamide refers to amino, monoalkylamino, dialkylamino, monocycloalkylamino, alkylcycloalkylamino, and dicycloalkylamino radicals, attached to one of two unshared bonds in a carbonyl group.
  • nitro means -NO 2 -.
  • a radical in a cyclohexanehexol may be substituted with one or more substituents apparent to a person skilled in the art including without limitation alkyl, alkenyl, alkynyl, alkanoyl, alkylene, alkenyl ene, hydroxyalkyl, haloalkyl, haloalkylene, haloalkenyl, alkoxy, alkenyloxy, alkenyloxyalkyl, alkoxyalkyl, aryl, alkylaryl, haloalkoxy, haloalkenyloxy, heterocyclic, heteroaryl, sulfonyl, sulfenyl, alkylsulfonyl, sulf ⁇ nyl, alkylsulfinyl, aralkyl, heteroaralkyl, cycloalkyl, cycloalkenyl, cycloalkoxy, cycloalkenyloxy, amino, oxy, hal
  • the cyclohexanehexol is an isolated, in particular pure, more particularly substantially pure, compound of the formula I, wherein X is a radical of scyllo-inositol, epi-inositol or a configuration isomer thereof, wherein
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, or
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R are independently optionally substituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyanato, halo, seleno, silyl, silyloxy, silylthi
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, or
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently optionally substituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfinyl, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyanato, halo, seleno, silyl, silyloxy, silyl
  • a cyclohexanehexol does not include a compound of the formula I or II where (a) when one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl or fluorine, more than 4 of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, (b) when one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is amino or azide, more than four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, (c) when two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are amino, more than three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and (d) R 1
  • a cyclohexanehexol is utilized where one or more of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, alkoxy, or halo, and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is hydrogen.
  • the cyclohexanehexol is a compound of the formula I or II where the hydrogen at one or more of positions 1, 2, 3, 4, 5, or 6 of formula I or II is substituted with a radical disclosed herein for R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , including optionally substituted alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfinyl, sulfonate, amino, imino, azido, thiol, thioalkyl, thioalk
  • the cyclohexanehexol is a compound of the formula I or II wherein one or more of, two or more of, or three or more of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfenyl, sulfinyl, sulfonate, sulfoxide, sulfate, nitro, cyano, isocyanato, thioaryl, thioalkoxy, seleno, silyl, silyloxy, silylthio, Cl, I, Br, carboxyl,
  • the cyclohexanehexol is an isolated, in particular pure, more particularly, substantially pure, compound of the formula I or II wherein one or more of, two or more of, or three or more of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently CpC 6 alkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkylene, C 2 -C 8 alkenylene, Ci-C 6 alkoxy, C 2 -C 6 alkenyloxy, C 3 -Cg cycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 cycloalkoxy, C 3 -C 8 cycloalkoxy, acyloxy, sulfonyl, sulfenyl, sulfinyl, sulfonate, sulfoxide, sulf
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl or fluorine no more than 4 of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl
  • Rb when one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is amino no more than four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl
  • Rd R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are not isopropylidene.
  • the cyclohexanehexol is a compound of the formula I wherein R 2 is hydroxyl in an equatorial position, at least one, two, three, or four of R 1 , R 3 , R 4 , R 5 , and/or R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfenyl, sulfonyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyan
  • the cyclohexanehexol is a compound of the formula I wherein R 2 is hydroxyl in an equatorial position, at least two of R 1 , R 3 , R 4 , R 5 , and/or R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyanato
  • the cyclohexanehexol is a compound of the formula I or II wherein at least two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and one, two, three or four or more of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thio
  • the cyclohexanehexol is a compound of the formula I or II wherein at least two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and two or more of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, or acyloxy, sulfonyl, sulfenyl, sulfinyl, amino, imino, cyano, isocyanato, seleno, silyl, silyloxy, silylthio,
  • the cyclohexanehexol is a compound of the formula I or II wherein at least two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and three or more of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thio
  • the cyclohexanehexol is a compound of the formula I or II wherein at least three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and one, two, or three of the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol,
  • the cyclohexanehexol is a compound of the formula I or II wherein at least four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, and one or two of the other of R 1 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfonate, sulfenyl, sulfinyl, amino, imino, azido, thiol, thioalkyl,
  • the cyclohexanehexol is a compound of the formula I or II wherein R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl, and R 3 is alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, azido, nitro, cyano, isocyanato, halo, selen
  • R 3 is selected from the group consisting of alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, imino, heteroaryl, heterocyclic, acyl, acyloxy, sulfonyl, sulfenyl, sulfinyl, sulfoxide, sulfate, thioalkoxy, thioaryl, carboxyl, carbonyl, carbamoyl, or carboxamide, in particular alkoxy, sulfonyl, sulfenyl, sulfinyl, sulfoxide, sulfate, thioalkoxy, carboxyl, carbonyl, carbamoyl, or carboxamide.
  • R 3 is selected from the group consisting Of C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkylene, C 2 -C 8 alkenylene, Ci-C 6 alkoxy, C 2 -C 6 alkenyloxy, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 cycloalkoxy, aryl, aryloxy, arylCi-C 6 alkoxy, acetyl, halo, and carboxylic ester, in particular Ci-C 6 alkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkylene, C 2 -C 8 alkenylene, Ci-C 6 alkoxy, C 2 -C 6 alkenyloxy, C 3 -C 8 cycloalkyl,
  • the cyclohexanehexol is a compound of the formula I or II wherein R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl, and R 2 is alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, azido, nitro, cyano, isocyanato, halo, selen
  • R 2 is selected from the group consisting of CJ-C 6 alkyl, C 3 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkylene, C 2 -C 8 alkenylene, C 1 -C 6 alkoxy, C 2 -C 6 alkenyloxy, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, C 3 -C 8 cycloalkoxy, aryl, aryloxy, arylCi-C 6 alkoxy, acetyl, halo, and carboxylic ester.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein one, two, three, four or five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are each independently: (a) alkyl with 1 to 24 carbon atoms, in particular 1 to 10 or 1 to 6 carbon atoms;
  • heterocyclic group comprising 3 to 10, in particular 3 to 8 or 3 to 6 ring members and at least one atom selected from the group consisting of oxygen, nitrogen, and sulfur;
  • halo in particular fluorine, chlorine, or bromine, especially chlorine.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 2 is hydroxyl and one, two, three, four or five of R 1 , R 3 , R 4 , R 5 , and/or R 6 is each independently methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, eicosyl, docosyl, methoxy, ethoxy, propoxy, butoxy, isopropoxy, tert-butoxy, chloro, cyclopropyl, cyclopentyl, cyclohexyl, vinyl, allyl, propenyl, octadie
  • the cyclohexanehexol is a compound of the formula
  • R 1 is hydroxyl and one, two, three, four or five of R 2 , R 3 , R 4 , R 5 , and/or
  • R 6 is each independently methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, eicosyl, docosyl, methoxy, ethoxy, propoxy, butoxy, isopropoxy, tert-butoxy, chloro, cyclopropyl, cyclopentyl, cyclohexyl, vinyl, allyl, propenyl, octadienyl, octenyl, decenyl, dodecenyl, tetradecenyl, hexadecenyl, octadecenyl, octadecadienyl, nonadec
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein one or two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are carboxyl, carbamyl, sulfonyl, or a heterocyclic comprising a N atom, more particularly N-methylcarbamyl, N-propylcarbamyl, N-cyanocarbamyl, aminosulfonyl, isoxazolyl, imidazolyl, and thiazolyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV where R 2 is hydroxyl; and R 1 , R 3 , R 4 , R 5 , and R 6 are independently selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 C 6 alkoxy, C 2 -C 6 alkenyloxy,
  • R 2 is hydroxyl; one of R 1 , R 3 , R 4 , R 5 , and R 6 is hydroxyl; and four of R 1 , R 3 , R 4 , R 5 , and R 6 are independently selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, CiQalkoxy, C 2 -C 6 alkenyloxy, C 3 -C I0 cycloalkyl, C 4 -Ci 0 cycloalkenyl, C 3 -Ci 0 cycloalkoxy, C 6 -Ci O aryl, C 6 -C ]0 aryloxy, C 6 -Ci 0 aryl-Ci-C 3 alkoxy, C 6 -Ci 0 aroyl, C 6 -C 10 heteroaryl, C 3 -Ci 0 heterocyclic, Ci-C 6 acyl, C r C 6
  • the cyclohexanehexol is a compound of the formula I, II, III or IV where R 2 is hydroxyl; two of R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl; and three of R 1 , R 3 , R 4 , R 5 , and R 6 are independently selected from C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, QQalkoxy, C 2 -C 6 alkenyloxy, C 3 -C] 0 cycloalkyl, C 4 -Ci 0 cycloalkenyl, C 3 -Ci 0 CyClOaIkOXy, C 6 -Ci 0 aryl, C 6 -Ci 0 aryloxy, C 6 -Ci 0 aryl-Ci-C 3 alkoxy, C 6 -Ci 0 aroyl, C 6
  • the cyclohexanehexol is a compound of the formula III or IV where R 2 is hydroxyl; three of R 1 , R 3 , R 4 , R 5 , and R 6 is hydroxyl; and two of R 1 , R 3 , R 4 , R 5 , and R 6 are independently selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 QaIkOXy, C 2 -C 6 alkenyloxy, C 3 -C 10 cycloalkyl, C 4 -C 1 ocycloalkenyl, C 3 -Ci 0 cycloalkoxy, C 6 -C 10 aryl, C 6 -Ci 0 aryloxy, C 6 -C 10 aryl-C]-C 3 alkoxy, C 6 -C 10 aroyl, C 6 -C 10 heteroaryl,
  • the cyclohexanehexol is a compound of the formula III or IV where R 2 is hydroxyl; four of R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl; and one of R 1 , R 3 , R 4 , R 5 , and R 6 are independently selected from C !
  • the cyclohexanehexol is a compound of the formula III or IV wherein two of R 1 , R 3 , R 4 , R 5 , and R 6 are Ci-C 6 alkyl, Ci-C 6 alkoxy, C
  • R 7 R 8 are as defined above; and no more than two of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein one, two, three, four or five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido,
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein one, two, or three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is each independently -OR 17 where R 17 is alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyan
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is each independently -OR 17 where R 17 is Ci-C 6 alkyl, most particularly Ci-C 3 alkyl.
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is -OR 20 wherein R 20 is - CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R , R , R 3 , R 5 , and R 6 are hydroxyl and R 4 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, which may be substituted with alkyl, halo (e.g., fluoro), substituted alkyl (e.g.
  • R 2 , R , R 4 , R 5 , and R 6 are hydroxyl and R 1 is -OR 20 wherein R 20 is CF 3 , CF 3 CF 2 , CF 3 CH 2 , CH 2 NO 2 , CH 2 NH 2 , C(CH 2 ) 3 , or cyclopropyl.
  • R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is methoxy.
  • the cyclohexanehexol is a compound of the formula III or IV, wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl; and one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is C ! -C 6 alkoxy; for example at least one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is methoxy.
  • R 7 and R 8 are independently selected from d-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, C 4 -C 10 cycloalkenyl, C 6 -Ci 0 aryl, C 6 -Ci 0 aryl Ci-C 3 alkyl, C 6 -Ci O heteroaryl and C 3 -Ci 0 heterocyclic.
  • the cyclohexanehexol is a compound of the formula IV, wherein R 1 is Ci-C 6 alkoxy; and R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl; for example R 1 is methoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with alkyl, in particular Ci-C 6 alkyl, more particularly Ci-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with halo (e.g., fluoro, chloro or bromo) which may be substituted.
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is fluoromethoxy, chloromethoxy, trifiuoromethoxy, difluoromethoxy, trifiuoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is a haloalkoxyalkyl, in particular fluoromethoxymethyl, chloromethoxyethyl, trifluoromethoxymethyl, difluoromethoxy ethyl, or trifluoroethoxymethyl.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl, more particularly Cj-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl, more particularly Ci-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl, more particularly Ci-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl, more particularly Ci-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula
  • R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is substituted alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy substituted with alkyl, in particular lower alkyl, more particularly Ci-C 3 alkyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is fluoromethoxy, chloromethoxy, trifluoromethoxy, difiuoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is is fluoromethoxy, chloromethoxy, trifluoromethoxy, difiuoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is is fluoromethoxy, chloromethoxy, trifluoromethoxy, difiuoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is is fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is alkoxy, in particular alkoxy having about 1 -6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is is fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is alkoxy, in particular alkoxy having about 1-6 carbon atoms, more particularly methoxy, ethoxy, propoxy, butoxy, isopropoxy and tert-butoxy, substituted with halo (e.g., fluoro, chloro or bromo).
  • halo e.g., fluoro, chloro or bromo
  • R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is is fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, or fluoropropoxy.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein one, two, three, four or five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido,
  • At least one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl and the other of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is a carboxylic ester.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein at least one of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is a carboxylic ester.
  • R 6 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is a carboxylic ester.
  • R 5 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula
  • R 4 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R , R 4 , R 5 , and R 6 are hydroxyl and R 3 is a carboxylic ester.
  • R 3 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is a carboxylic ester.
  • R 2 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is a carboxylic ester.
  • R 1 is -C(O)OR 14 where R 14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, amino, thiol, aryl, heteroaryl, thioalkyl, thioaryl, thioalkoxy, or a heterocyclic ring, which may optionally be substituted, in particular substituted with alkyl substituted with one or more of alkyl, amino, halo, alkylamino, aryl, carboxyl, aryl, or a heterocyclic.
  • R 14 is selected to provide an amino acid derivative or an ester derivative.
  • R 14 is one of the following:
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is each independently:
  • R 30 is alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyanato, halo, seleno, silyl, silyloxy, silylthio, carboxyl, carboxylic ester, carbonyl, carbamoyl, or carboxamide, and the other of R 1 , R 2 , R 3 , R
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein at least one, two, three or four of R 1 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 3 , R 4 , R 5 , and/or R 6 are alkyl, halo, alkoxy, sulfonyl, sulfinyl, thiol, thioalkyl, thioalkoxy, carboxyl, in particular C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or halo.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein at least one, two, three or four of R 1 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R 3 , R 4 , R 5 , and/
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 is each independently -CH 3 , -OCH 3 , F, N 3 , NH 2 , SH, NO 2 , CF 3 , OCF 3 , SeH, Cl, Br, I or CN with the proviso that four or five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 , and more particularly R 2 or R 3 , is selected from the group consisting of -CH 3 , -OCH 3 , CF 3 , F, SH, SeH, Cl, Br, I and CN.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are selected from the group consisting of-CH 3 , -OCH 3 , CF 3 , F, -NO 2 , SH, SeH, Cl, Br, I and CN.
  • the cyclohexanehexol is a compound of the formula III or IV, wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl; and one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is each independently selected from the group CH 3 , OCH 3 , NO 2 , CF 3 , OCF 3 , F, SH, Cl, Br, I and CN.
  • the cyclohexanehexol is a compound of the formula III or IV, wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl; and one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is each independently selected from the group CH 3 , OCH 3 , NO 2 , CF 3 , OCF 3 , F, SH, Cl, Br, I and CN.
  • R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 are hydroxyl; and one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 is selected from CH 3 , OCH 3 , NO 2 , CF 3 , OCF 3 , SH, F, Cl, Br, I and CN.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are lower alkyl, especially methyl, ethyl, butyl, or propyl, preferably methyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other two of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are lower cycloalkyl, especially cyclopropyl, cyclobutyl, and cyclopentyl.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein two, three, four or five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thio
  • R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, isocyan
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein three of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein four of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl, the other of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are independently hydrogen, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, sulfoxide, sulfate, sulfonyl, sulfenyl, sulfonate, sulfinyl, amino, imino, azido, thiol, thioal
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R , R , R , R , and/or R is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 , R 3 , R 4 , R 5 , and/or R 6 are hydroxyl and the other of R 1 , R , R , R , R , and/or R is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein five of R 1 , R 2 ,
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is halo, in particular fluorine, chlorine or bromine, more particularly chloro.
  • R 1 , R 2 , R 3 , R 4 , and R 5 are hydroxyl and R 6 is chloro.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 2 , R 3 , R 4 , and R 6 are hydroxyl and R 5 is chloro.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 1 , R 2 , R 3 , R 5 , and R 6 are hydroxyl and R 4 is chloro.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 1 , R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 2 , R 4 , R 5 , and R 6 are hydroxyl and R 3 is chloro.
  • the cyclohexanehexol is a compound of the formula
  • R 1 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 2 is chloro.
  • the cyclohexanehexol is a compound of the formula I, II, III or IV wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 2 is a compound of the formula I, II, III or IV wherein R 2 , R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is halo, in particular fluoro, chloro or bromo, more particularly chloro.
  • R 3 , R 4 , R 5 , and R 6 are hydroxyl and R 1 is chloro.
  • the cyclohexanehexol is a scyllo-inositol compound, in particular a pure or substantially pure scyllo-inositol compound.
  • a "scyllo-inositol compound” includes compounds having the structure of the formula
  • a scyllo-inositol compound includes a compound of the formula Va or Vb wherein one to six, one to five, one, two, three or four, preferably one, two or three, more preferably one or two hydroxyl groups are replaced by substituents, in particular univalent substituents, with retention of configuration.
  • a scyllo-inositol compound comprises a compound of the formula Va or Vb wherein one, two, three, four, five or six, preferably one or two, most preferably one, hydroxyl groups are replaced by univalent substituents, with retention of configuration.
  • Suitable substituents include without limitation hydrogen; alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; cycloalkyl; substituted cycloalkyl; alkoxy; substituted alkoxy; aryl; aralkyl; substituted aryl; halogen; thiol; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -PO 3 H 2 ; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; or -OR 45 wherein R 45 is hydrogen, alkyl, or -SO 3 H.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl, in particular C 1 -C 4 alkyl, more particularly methyl; acyl; chloro or fluoro; alkenyl; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; and -OR 45 wherein R 45 is hydrogen, alkyl, or -SO 3 H, more particularly -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H or -OR 45 wherein R 45 is -SO 3 H.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substitututed alkenyl; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl, or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; or -OR 45 wherein R 45 is hydrogen, alkyl or -SO 3 H.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; alkoxy; substituted alkoxy; halogen; thiol; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -PO 3 H 2 ; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; -OR 45 wherein R 45 is hydrogen, alkyl, or -OR 45 wherein R 45 is -SO 3 H.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; alkoxy; substituted alkoxy; halogen; or thiol.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with alkyl, in particular Ci-C 4 alkyl, more particularly methyl.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with halogen, in particular chloro or fluoro, more particularly fluoro.
  • Particular aspects of the invention utilize scyllo-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with thiol.
  • the scyllo-inositol compound designated AZD- 103/ ELND005 (Elan Corporation) is used in the formulations, dosage forms, methods and uses disclosed herein.
  • the cyclohexanehexol is methyl-scyllo-inositol
  • the cyclohexanehexol is 1 -chloro- 1-deoxy-scy Ho- inositol.
  • the cyclohexanehexol is an epi-inositol compound, in particular a pure or substantially pure epi-inositol compound.
  • An "epi-inositol compound” includes compounds having the base structure of formula
  • An epi-inositol compound includes a compound of the formula VI wherein one to six, one to five, one, two, three or four, preferably one, two or three, more preferably one or two hydroxyl groups are replaced by substituents, in particular univalent substituents, with retention of configuration.
  • an epi-inositol compound comprises a compound of the formula VI wherein one, two, three, four, five or six, preferably one or two, most preferably one, hydroxyl groups are replaced by univalent substituents, with retention of configuration.
  • Suitable substituents include without limitation hydrogen; alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; cycloalkyl; substituted cycloalkyl; alkoxy; substituted alkoxy; aryl; aralkyl; substituted aryl; halogen; thiol; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -PO 3 H 2 ; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; or -OR 45 wherein R 45 is hydrogen, alkyl, or -SO 3 H.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl, in particular C 1 -C 4 alkyl, more particularly methyl; acyl; chloro or fluoro; alkenyl; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; and -OR 45 wherein R 45 is hydrogen, alkyl, or -SO 3 H, more particularly -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H or -OR 45 wherein R 45 is -SO 3 H.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or
  • Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substitututed alkenyl; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl, or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; or -OR 45 wherein R 45 is hydrogen, alkyl or -SO 3 H.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; alkoxy; substituted alkoxy; halogen; thiol; -NHR 41 wherein R 41 is hydrogen, acyl, alkyl or -R 42 R 43 wherein R 42 and R 43 are the same or different and represent acyl or alkyl; -PO 3 H 2 ; -SR 44 wherein R 44 is hydrogen, alkyl, or -O 3 H; -OR 45 wherein R 45 is hydrogen, alkyl, or -OR 45 wherein R 45 is -SO 3 H.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one or more of the hydroxyl groups is replaced with alkyl; substituted alkyl; acyl; alkenyl; substituted alkenyl; alkynyl; substituted alkynyl; alkoxy; substituted alkoxy; halogen; or thiol.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with alkyl, in particular Ci-C 4 alkyl, more particularly methyl.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with halogen, in particular chloro or fluoro, more particularly fluoro.
  • Particular aspects of the invention utilize epi-inositol compounds of the formula Va or Vb wherein one of the hydroxyl groups is replaced with thiol.
  • the cyclohexanehexol is epi-inositol, in particular a pure or substantially pure epi-inositol.
  • Cyclohexanehexols utilized in the invention may be prepared using reactions and methods generally known to the person of ordinary skill in the art, having regard to that knowledge and the disclosure of this application.
  • the reactions are performed in a solvent appropriate to the reagents and materials used and suitable for the reactions being effected.
  • the functionality present on the compounds should be consistent with the proposed reaction steps. This will sometimes require modification of the order of the synthetic steps or selection of one particular process scheme over another in order to obtain a desired compound of the invention.
  • Another major consideration in the development of a synthetic route is the selection of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention.
  • An authoritative account describing the many altematives to the skilled artisan is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991).
  • the starting materials and reagents used in preparing cyclohexanehexols are either available from commercial suppliers such as the Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or Lancaster Synthesis Inc. (Windham, N. H.) or are prepared by methods well known to a person of ordinary skill in the art, following procedures described in such references as Fieser and Fieser's Reagents for Organic Synthesis, vols. 1-17, John Wiley and Sons, New York, N. Y., 1991; Rodd's Chemistry of Carbon Compounds, vols.
  • the starting materials, intermediates, and cyclohexanehexols may be isolated and purified using conventional techniques, such as precipitation, filtration, distillation, crystallization, chromatography, and the like.
  • the compounds may be characterized using conventional methods, including physical constants and spectroscopic methods, in particular HPLC.
  • Cyclohexanehexols which are basic in nature can form a wide variety of different salts with various inorganic and organic acids.
  • the acid addition salts of the base compounds are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.
  • Cyclohexanehexols which are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. These salts may be prepared by conventional techniques by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are typically employed to ensure completeness of reaction and maximum product yields.
  • Scyllo-inositol compounds may be prepared using conventional processes or they may be obtained from commercial sources.
  • scyllo-inositol compounds can be prepared using chemical and/or microbial processes.
  • a scyllo- inositol is produced using process steps described by M. Sarmah and Shashidhar, M., Carbohydrate Research, 2003, 338, 999-100, Husson, C, et al, Carbohyrate Research 307 (1998) 163-165; Anderson R. and E.S. Wallis, J.
  • a scyllo-inositol is prepared using the chemical process steps described in Husson, C, et al, Carbohydrate Research 307 (1998) 163-165.
  • a scyllo-inositol is prepared using microbial process steps similar to those described in WO05035774 (EPl 674578 and US20060240534) JP2003102492, or JP09140388 (Hokko Chemical Industries).
  • Derivatives may be produced by introducing substituents into a scyllo-cyclohexanehexol using methods well known to a person of ordinary skill in the art.
  • an epi-inositol can be prepared using chemical and/or microbial processes.
  • an epi-inositol may be prepared by the process described by V. Pistara (Tetrahedron Letters 41, 3253, 2000), Magasanik B., and Chargaff E. (J Biol Chem, 1948, 174:173188), US Patent No. 7,157,268, or in PCT Published Application No. WO0075355.
  • Derivatives may be produced by introducing substituents into an epi-inositol using methods well known to a person of ordinary skill in the art.
  • a cyclohexanehexol may additionally comprise a carrier, including without limitation one or more of a polymer, carbohydrate, peptide or derivative thereof.
  • a carrier may be substituted with substituents described herein including without limitation one or more alkyl, amino, nitro, halogen, thiol, thioalkyl, sulfate, sulfonyl, sulfenyl, sulfinyl, sulfoxide, hydroxyl groups.
  • a carrier can be directly or indirectly covalently attached to a compound of the invention.
  • the carrier is an amino acid including alanine, glycine, proline, methionine, serine, threonine, or asparagine.
  • the carrier is a peptide including alanyl-alanyl, prolyl-methionyl, or glycyl-glycyl.
  • a carrier also includes a molecule that targets a cyclohexanehexol to a particular tissue or organ.
  • a carrier may facilitate or enhance transport of a compound of the invention to the brain by either active or passive transport.
  • a "polymer” as used herein refers to molecules comprising two or more monomer subunits that may be identical repeating subunits or different repeating subunits.
  • a monomer generally comprises a simple structure, low-molecular weight molecule containing carbon.
  • Polymers can be optionally substituted. Examples of polymers which can be used in the present invention are vinyl, acryl, styrene, carbohydrate derived polymers, polyethylene glycol (PEG), polyoxyethylene, polymethylene glycol, poly-trimethylene glycols, polyvinylpyrrolidone, polyoxyethylene-polyoxypropylene block polymers, and copolymers, salts, and derivatives thereof.
  • the polymer is poly(2- acrylamido-2-methyl- 1 -propanesulfonic acid); poly(2-acrylamido-2-methyl,- 1 - propanesulfonic acid-coacrylonitrile, poly(2-acrylamido-2-methyl-l -propanesulfonic acid-co- styrene), poly(vinylsulfonic acid); poly(sodium 4-styrenesulfonic acid); and sulfates and sulfonates derived therefrom; poly(acrylic acid), poly(methylacrylate), poly(methyl methacrylate), and poly(vinyl alcohol).
  • a “carbohydrate” as used herein refers to a polyhydroxyaldehyde, or polyhydroxyketone and derivatives thereof.
  • the simplest carbohydrates are monosaccharides, which are small straight-chain aldehydes and ketones with many hydroxyl groups added, usually one on each carbon except the functional group. Examples of monosaccharides include erythrose, arabinose, allose, altrose, glucose, mannose, threose, xylose, gulose, idose, galactose, talose, aldohexose, fructose, ketohexose, ribose, and aldopentose.
  • Other carbohydrates are composed of monosaccharide units, including disaccharides, oligosaccharides, or polysaccharides, depending on the number of monosaccharide units.
  • Disaccharides are composed of two monosaccharide units joined by a covalent glycosidic bond. Examples of disaccharides are sucrose, lactose, and maltose.
  • Oligosaccharides and polysaccharides are composed of longer chains of monosaccharide units bound together by glycosidic bonds. Oligosaccharides generally contain between 3 and 9 monosaccharide units and polysaccharides contain greater than 10 monosaccharide units.
  • a carbohydrate group may be substituted at one two, three or four positions, other than the position of linkage to a compound of the formula I, II, III or IV.
  • a carbohydrate may be substituted with one or more alkyl, amino, nitro, halo, thiol, carboxyl, or hydroxyl groups, which are optionally substituted.
  • Illustrative substituted carbohydrates are glucosamine or galactosamine.
  • the carbohydrate is a sugar, in particular a hexose or pentose and may be an aldose or a ketose.
  • a sugar may be a member of the D or L series and can include amino sugars, deoxy sugars, and their uronic acid derivatives.
  • the hexose is selected from the group consisting of glucose, galactose, or mannose, or substituted hexose sugar residues such as an amino sugar residue such as hexosamine, galactosamine, glucosamine, in particular D-glucosamine (2-amino-2-doexy-D-glucose) or D-galactosamine (2-amino-2-deoxy-D- galactose).
  • Suitable pentose sugars include arabinose, fucose, and ribose.
  • carbohydrate also includes glycoproteins such as lectins (e.g. concanavalin
  • A wheat germ agglutinin, peanutagglutinin, seromucoid, and orosomucoid
  • glycolipids such as cerebroside and ganglioside.
  • a “peptide” for use as a carrier in the practice of the present invention includes one, two, three, four, or five or more amino acids covalently linked through a peptide bond.
  • a peptide can comprise one or more naturally occurring amino acids, and analogs, derivatives, and congeners thereof.
  • a peptide can be modified to increase its stability, bioavailability, solubility, etc.
  • Peptide analogue and “peptide derivative” as used herein include molecules which mimic the chemical structure of a peptide and retain the functional properties of the peptide.
  • the carrier is an amino acid such as alanine, glycine, proline, methionine, serine, threonine, histidine, or asparagine.
  • the carrier is a peptide such as alanyl-alanyl, prolyl-methionyl, or glycyl-glycyl.
  • the carrier is a polypeptide such as albumin, antitrypsin, macroglobulin, haptoglobin, caeruloplasm, transferrin, ⁇ - or ⁇ - lipoprotein, ⁇ - or ⁇ - globulin or fibrinogen.
  • peptide analogues, derivatives and peptidomimetics examples include peptides substituted with one or more benzodiazepine molecules (see e.g., James, G. L. et al. (1993) Science 260:1937-1942), peptides with methylated amide linkages and "retro-inverso" peptides (see U.S. Pat. No. 4,522,752 by Sisto).
  • peptide derivatives include peptides in which an amino acid side chain, the peptide backbone, or the amino- or carboxy-terminus has been derivatized (e.g., peptidic compounds with methylated amide linkages).
  • mimetic and in particular, peptidomimetic, is intended to include isosteres.
  • isostere refers to a chemical structure that can be substituted for a second chemical structure because the steric conformation of the first structure fits a binding site specific for the second structure.
  • the term specifically includes peptide back-bone modifications (i.e., amide bond mimetics) well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the alpha-carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks.
  • isosteres include peptides substituted with one or more benzodiazepine molecules (see e.g., James, G. L. et al. (1993) Science 260:1937-1942)
  • the parent peptide is Thr-Ala-Tyr
  • the retro modified form is Tyr-Ala-Thr
  • the inverso form is thr-ala-tyr
  • the retro-inverso form is tyr-ala-thr (lower case letters refer to D-amino acids).
  • a retro-inverso peptide has a reversed backbone while retaining substantially the original spatial conformation of the side chains, resulting in a retro-inverso isomer with a topology that closely resembles the parent peptide. See Goodman et al. "Perspectives inPeptide Chemistry" pp. 283-294 (1981).
  • a peptide can be attached to a cyclohexanehexol through a functional group on the side chain of certain amino acids (e.g. serine) or other suitable functional groups.
  • the carrier may comprise four or more amino acids with groups attached to three or more of the amino acids through functional groups on side chains.
  • the carrier is one amino acid, in particular a sulfonate derivative of an amino acid, for example cysteic acid.
  • secretase inhibitor refers to a compound that is an effective inhibitor of a secretase associated with A ⁇ production or aggregation, or amyloid beta deposits or plaques. Examples of secretase inhibitors include beta-secretase inhibitors and gamma-secretase inhibitors.
  • beta-secretase inhibitor refers to an agent that is an effective inhibitor of a beta- secretase and/or A ⁇ production, inhibits beta-secretase modulated cleavage of APP, and/or is effective to reduce amyloid beta deposits or plaques. All beta-secretase mediated treatments suggested for the treatment and prevention of a disease disclosed herein, including Alzheimer's disease, are included in the term beta-secretase inhibitors. Illustrations of and non limiting examples of beta-secretase inhibitors are disclosed in the references listed in Table 1.
  • the beta-secretase inhibitor is PNU-33312; a macrocyclic peptidomimetic inhibitor [Rojo I et al., Bioorg Med Chem Lett.2006 Jan 1; 16(1): 191 -195], a heparin sulphate analog [Patey SJ, Biochem Soc Trans. 2005 Oct;33(Pt 5):1116-8], 1,2,3- trigalloyl-4,6-hexahydroxydiphenoyl-beta-D-glucopyranoside (Tellimagrandin II, I) or 1,2,3,4,6-pentagalloyl-beta-D-glucopyranoside [Lee HJ et al, Arch Pharm Res.
  • a "gamma-secretase inhibitor” refers to an agent that is an effective inhibitor of gamma-secretase and/or A ⁇ production, inhibits gamma-secretase-mediated cleavage of APP, and/or is effective to reduce amyloid beta deposits or plaques. All gamma-secretase mediated treatments suggested for the treatment and prevention of a disease disclosed herein, including Alzheimer's disease are included in the term gamma-secretase inhibitors as used herein. Illustrations of and non limiting examples of gamma-secretase inhibitors are disclosed in the references listed in Table 2.
  • a potent selective and cell permeable gamma-secretase inhibitor is utilized, in particular (5S)-(t-Butoxycarbonylamino)-6-phenyl- (4R)hydroxy-(2R)benzylhexanoyl)-L-leu-L-phe-amide.
  • the gamma-secretase inhibitor is N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-Nl-[(7S)-5-methyl-6-oxo- 6,7-dihydro-5Hdibenzo [b,d]azepin-7-yl]-L-alaninamide (LY-411575) (Best JD J Pharmacol Exp Ther. 2005 Mar 2; : Lanz TA, J Pharmacol Exp Ther. 2004 Apr;309(l):49-55).
  • the gamma-secretase inhibitor is N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester [Dovey HF, J Neurochem. 2001 Jan;76(l):173-81].
  • a gamma-secretase inhibitor is a non-steroidal anti-inflammatory drug (NSAID) including without limitation Curcumin C3 complex [Yang F et al, J Biol Chem. 2005 Feb 18;280(7):5892-901; Lim GP et al J Neurosci.
  • NSAID non-steroidal anti-inflammatory drug
  • the gamma-secretase inhibitor is a thiazole diamide (Yuhpyng, L.
  • the gamma-secretase inhibitor is LY450139 (Eli Lilly) or MRK-003 (Merck).
  • a cyclohexanehexol and/or secretase inhibitor may be pure or substantially pure.
  • pure means better than 90%, 92%, 94%, 95%, 98% or 99% pure
  • substantially pure means a compound synthesized such that the compound, as made available for consideration into a therapeutic dosage, has only those impurities that can not readily nor reasonably be removed by conventional purification processes.
  • a “disease(s)” refers to one or more pathological symptoms or syndromes for which either or both a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor provide a therapeutic effect.
  • a “disease(s)” includes a condition characterized by abnormal protein folding or aggregation or abnormal amyloid formation, deposition, accumulation or persistence, or amyloid lipid interactions. In some aspects, the term includes conditions characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence. In particular aspects, the disease is a condition of the central or peripheral nervous system or systemic organ.
  • the terms include conditions associated with the formation, deposition, accumulation, or persistence of amyloid or amyloid fibrils, comprising an amyloid protein comprising or selected from the group consisting of A ⁇ amyloid, AA amyloid, AL amyloid, IAPP amyloid, PrP amyloid, ⁇ 2 -microglobulin amyloid, transthyretin, prealbumin, and procalcitonin, especially A ⁇ amyloid and IAPP amyloid.
  • a disease may be a condition where it is desirable to dissociate abnormally aggregated proteins and/or dissolve or disrupt pre-formed or pre-deposited amyloid or amyloid fibril.
  • the disease is an amyloidosis.
  • Amyloidosis refers to a diverse group of diseases of acquired or hereditary origin and characterized by the accumulation of one of several different types of protein fibrils with similar properties called amyloid. Amyloid can accumulate in a single organ or be dispersed throughout the body. The disease can cause serious problems in the affected areas, which may include the heart, brain, kidneys and digestive tract. The fibrillar composition of amyloid deposits is an identifying characteristic for various amyloid diseases.
  • Intracerebral and cerebrovascular deposits composed primarily of fibrils of beta amyloid peptide ( ⁇ -AP or A ⁇ ) are characteristic of Alzheimer's disease (both familial and sporadic forms); islet amyloid protein peptide (IAPP; amylin) is characteristic of the fibrils in pancreatic islet cell amyloid deposits associated with type II diabetes; and, ⁇ -2-microglobulin is a major component of amyloid deposits which form as a consequence of long term hemodialysis treatment.
  • Prion-associated diseases such as Creutzfeld-Jacob disease, scrapie, bovine spongiform encephalitis, and the like are characterized by the accumulation of a protease-resistant form of a prion protein (designated as AScr ro PrP-27).
  • Certain disorders are considered to be primary amyloidoses, in which there is no evidence for preexisting or coexisting disease.
  • Primary amyloidoses are typically characterized by the presence of "amyloid light chain-type" (AL-type) protein fibrils.
  • A-type amyloid light chain-type
  • secondary amyloidosis there is an underlying chronic inflammatory or infectious disease state (e.g., rheumatoid arthritis, juvenile chronic arthritis, ankylosing spondylitis, psoriasis, Reiter's syndrome, Adult Still's disease, Behcet's Syndrome, Crohn's disease, chronic microbial infections such as osteomyelitis, tuberculosis, and leprosy, malignant neoplasms such as Hodgkin's lymphoma, renal carcinoma, carcinomas of the gut, lung, and urogenital tract, basel cell carcinoma, and hairy cell carcinoma).
  • Amyloidosis is characterized by deposition of AA type fibrils derived from serum amyloid A protein (ApoSSA).
  • Amyloid A protein ApoSSA
  • Heredofamilial amyloidoses may have associated neuropathic, renal, or cardiovascular deposits of the ATTR transthyretin type, and they include other syndromes having different amyloid components (e.g., familial Mediterranean fever which is characterized by AA fibrils).
  • Other forms of amyloidosis include local forms, characterized by focal, often tumor-like deposits that occur in isolated organs.
  • amyloidoses are associated with aging, and are commonly characterized by plaque formation in the heart or brain.
  • Amyloidoses includes systemic diseases such as adult-onset disabetes, complications from long-term hemodialysis and consequences of chronic inflammation or plasma cell dyscrasias.
  • amyloid diseases that can be treated and/or prevented using a cyclohexanehexol compound and secretase inhibitor, compositions and methods of the invention include without limitation, Alzheimer's disease, Down's syndrome, dementia pugilistica, multiple system atrophy, inclusion body myositosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, Nieman-Pick disease type C, cerebral ⁇ - amyloid angiopathy, dementia associated with cortical basal degeneration, the amyloidosis of type II diabetes, the amyloidosis of chronic inflammation, the amyloidosis of malignancy and Familial Mediterranean Fever, the amyloidosis of multiple myeloma and B-cell dyscrasias, nephropathy with urticaria and deafness (Muckle - Wells syndrome), amyloidosis associated with systemic inflammatory diseases, idiopathic primary amyloidosis associated
  • diseases that can be treated and/or prevented using a cyclohexanehexol compound and secretase inhibitor, compositions and methods of the invention include conditions of the central or peripheral nervous system or a systemic organ that result in the deposition of proteins, protein fragments, and peptides in beta-pleated sheets, fibrils, and/or aggregates or oligomers.
  • the disease is Alzheimer's disease, presenile and senile forms; amyloid angiopathy; mild cognitive impairment; Alzheimer's disease-related dementia (e.g., vascular or Alzheimer dementia); tauopathy (e.g., argyrophilic grain dementia, corticobasal degeneration, dementia pugilistica, diffuse neurofibrillary tangles with calcification, frontotemporal dementia with parkinsonism, Prion-related disease, Hallervorden-Spatz disease, myotonic dystrophy, Niemann-Pick disease type C, non- Guamanian Motor Neuron disease with neurofibrillary tangles, Pick's disease, postencephalitic parkinsonism, cerebral amyloid angiopathy, progressive subcortical gliosis, progressive supranuclear palsy, subacute sclerosing panencephalitis, and tangle only dementia), alpha-synucleinopathy (e.g., dementia with Lewy bodies, multiple system
  • the disease is a neuronal disorder (e.g., Alzheimer's disease, Down Syndrome, Parkinson's disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, disorders including cognitive dysfunction and dementia).
  • a neuronal disorder e.g., Alzheimer's disease, Down Syndrome, Parkinson's disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, disorders including cognitive dysfunction and dementia).
  • the disease is a neurodegenerative disease or neurodegenerative disorder including such diseases and impairments as Alzheimer's disease, dementia, MCI, Huntington' s disease, Parkinson's disease, amyotrophic lateral sclerosis, epilepsy, Pick's disease, and other similar diseases and disorders disclosed herein.
  • a cyclohexanehexol compound and secretase inhibitor, compositions and methods of the invention may also act to inhibit or prevent ⁇ -synuclein/NAC fibril formation, inhibit or prevent ⁇ -synuclein/NAC fibril growth, and/or cause disassembly, disruption, and/or disaggregation of preformed ⁇ -synuclein/NAC fibrils and ⁇ -synuclein/NAC-associated protein deposits.
  • synuclein diseases or synucleinopathies suitable for treatment with a cyclohexanehexol compound and secretase inhibitor or composition of the invention are diseases associated with the formation, deposition, accumulation, or persistence of synuclein fibrils, especially ⁇ -synuclein fibrils, including without limitation Parkinson's disease, familial Parkinson's disease, Lewy body disease, the Lewy body variant of Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, olivopontocerebellar atrophy, neurodegeneration with brain iron accumulation type I, olfactory dysfunction, and the Parkinsonism-dementia complex of Guam.
  • Parkinson's disease familial Parkinson's disease
  • Lewy body disease the Lewy body variant of Alzheimer's disease
  • dementia with Lewy bodies dementia with Lewy bodies
  • multiple system atrophy olivopontocerebellar atrophy
  • neurodegeneration with brain iron accumulation type I olfactory dysfunction
  • the disease is a Motor Neuron Disease associated with filaments and aggregates of neurofilaments and/or superoxide dismutase proteins, the Spastic paraplegia associated with defective function of chaperones and/or triple A proteins and the spinocerebellar ataxia is DRPLA or Machado-Joseph Disease.
  • the disease is a Prion Disease including Creutzfeldt- Jakob disease,
  • Gerstmann-Strausller-Scheinfer disease and variant Creutzfeldt-Jakob disease and an Amyloid Polyneuropathy including senile amyloid polyneuropathy or systemic amyloidosis.
  • the disease is Alzheimer's disease or Parkinson's disease including familial and non-familial types.
  • the disease is Alzheimer's disease.
  • MMSE Mini-mental State Examination
  • CDR Clinical Dementia Rating
  • MMSE Mini-Mental State Examination
  • Functional Assessment e.g., using a Functional Assessment Staging (FAST) scale
  • FAST Functional Assessment Staging
  • ADAS-Cog Alzheimer's Disease Assessment Scale-Cognitive Subscale
  • senile or amyloid
  • amyloid angiopathy amyloid deposits in blood vessels
  • neurofibrillary tangles Large numbers of these lesions, particularly amyloid plaques and neurofibrillary tangles, are generally found in several areas of the human brain important for memory and cognitive function in patients with AD. Smaller numbers of these lesions in a more restricted anatomical distribution are also found in the brains of most aged humans who do not have clinical AD.
  • Amyloid plaques and amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D). Detection of such lesions, using MRI, CT, PET, SPECT, etc., is also useful in diagnosing AD.
  • the disease may be characterized by an inflammatory process due to the presence of macrophages by, an amyloidogenic protein or peptide.
  • a method of the invention may involve inhibiting macrophage activation and/or inhibiting an inflammatory process.
  • a method may comprise decreasing, slowing, ameliorating, or reversing the course or degree of macrophage invasion or inflammation in a patient.
  • a disease may be a condition that is associated with a molecular interaction that can be disrupted or dissociated with a compound of the invention.
  • a molecular interaction that can be disrupted or dissociated with a compound of the invention includes an interaction comprising an amyloid protein and a protein or glycoprotein.
  • An interaction comprising an amyloid protein includes an amyloid protein-amyloid protein interaction, amyloid-proteoglycan interaction, amyloid-proteoglycan/glycosaminoglycan (GAG) interaction and/or amyloid protein-glycosaminoglycan interaction.
  • An interacting protein may be a cell surface, secreted or extracellular protein.
  • a disease that may be treated or prevented using a cyclohexanehexol compound and secretase inhibitor or composition of the invention includes a disease that would benefit from the disruption or dissolution of a molecular interaction comprising an amyloid protein and an interacting compound including a protein or glycoprotein.
  • diseases that may be treated or prevented using a compound or composition of the invention include infectious diseases caused by bacteria, viruses, prions and fungi.
  • disorders and/or diseases are those associated with pathogens including Herpes simplex virus, Pseudorabies virus, human cytomegalovirus, human immunodeficiency virus, Bordetella pertussis, Chlamydia trachomatis, Haemophilus influenzae, Helicobacter pylori, Borrelia burgdorferi, Neisseria gonorrhoeae, Mycobacterium tuberculosis, Staphylococcus aureus, Streptococcus mutans, Streptococcus suis, Plasmodium falciparum, Leishmania amazonensi, Trypanozoma cruzi, Listeria monocytogenes, Mycoplasma pneumoniae, enterotoxigenic E. coli, uropathogenic E. coli, and Pseudomonas aeruginosa.
  • pathogens including Herpes simplex virus, Pseudorabies virus, human cytomegalovirus
  • interaction refers to any physical, association between proteins, other molecules such as lipids, carbohydrates, nucleotides, and other cell metabolites. Examples of interactions include protein-protein interactions.
  • the term preferably refers to a stable association between two molecules due to, for example, electrostatic, hydrophobic, ionic and/or hydrogen-bond interactions under physiological conditions. Certain interacting or associated molecules interact only after one or more of them have been stimulated (e.g. phosphorylated). An interaction between proteins and other cellular molecules may be either direct or indirect.
  • One or more cyclohexanehexol especially a scyllo-inositol compound and one or more secretase inhibitor, especially a beta-secretase inhibitor, may be formulated into a pharmaceutical composition for administration to a subject.
  • a pharmaceutical composition may be a formulation including without limitation pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium) suppositories, sterile injectable solutions, sustained release formulation, and/or sterile packaged powders, which comprise a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor in particular a pure or substantially pure scyllo-inositol compound and a beta-secretase inhibitor.
  • Various delivery systems are known and can be used to administer a composition of the invention, e.g. encapsulation in liposomes, microparticles, microcapsules, and the like.
  • compositions of the invention can be formulated as pharmaceutically acceptable salts as described herein.
  • compositions of the present invention or fractions thereof typically comprise suitable pharmaceutically acceptable carriers, excipients, and vehicles selected based on the intended form of administration, and consistent with conventional pharmaceutical practices.
  • Particular compositions of the invention may contain a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor that are pure or substantially pure.
  • Suitable pharmaceutical carriers, excipients, and vehicles are described in the standard text, Remington: The Science and Practice of Pharmacy (21 st Edition. 2005, University of the Sciences in Philadelphia (Editor), Mack Publishing Company), and in The United States Pharmacopeia: The National Formulary (USP 24 NF 19) published in 1999.
  • the compositions include without limitation at least one buffering agent or solution.
  • buffering agents include, but are not limited to hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, glucoronic, maleic, furoic, citric, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic, pamoic, methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, galacturonic acid and mixtures thereof.
  • Additional agents may also be included such as one or more of pregelatinized maize starch, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, lactose, microcrystalline cellulose, calcium hydrogen phosphate, magnesium stearate, talc, silica, potato starch, sodium starch glycolate, sodium lauryl sulfate, sorbitol syrup, cellulose derivatives, hydrogenated edible fats, lecithin, acacia, almond oil, oily esters, ethyl alcohol, fractionated vegetable oils, methyl, propyl-p- hydroxybenzoates, sorbic acid and mixtures thereof.
  • a buffering agent may additionally comprise one or more of dichlorodifiuoromethane, trichloro fluoromethane, dichlorotetra fluoroethane, carbon dioxide, poly (N-vinyl pyrrolidone), poly (methylmethacrylate), polyactide, polyglycolide and mixtures thereof.
  • a buffering agent can be formulated as at least one medium including without limitation a suspension, solution, or emulsion.
  • a buffering agent may additionally comprise a formulatory agent including without limitation a pharmaceutically acceptable carrier, excipient, suspending agent, stabilizing agent or dispersing agent.
  • a pharmaceutical composition for oral administration of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor for treatment of a disease.
  • a stable oral pharmaceutical composition for treatment of a disease characterized by abnormal protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence e.g., Alzheimer's disease
  • a substantially pure scyllo- inositol compound of the formula I, II, III, IV, V or VI preferably a compound of the formula V or VI
  • a secretase inhibitor in particular a beta secretase inhibitor.
  • a composition for oral administration can be in the form of a capsule or tablet, and the active components can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, methyl cellulose, magnesium stearate, glucose, calcium sulfate, dicalcium phosphate, mannitol, sorbital, and the like.
  • an oral, non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, methyl cellulose, magnesium stearate, glucose, calcium sulfate, dicalcium phosphate, mannitol, sorbital, and the like.
  • the drug components may be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • Suitable binders e.g. gelatin, starch, corn sweeteners, natural sugars including glucose; natural and synthetic gums, and waxes
  • lubricants e.g.
  • compositions as described herein can further comprise wetting or emulsifying agents, or pH buffering agents.
  • a pharmaceutical composition for parenteral administration of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor.
  • a parenteral formulation may include aqueous or non-aqueous solutions (e.g. water, isotonic saline, isotonic glucose solution, buffer solution, or other conventional solvents), syrups, aqueous or oil suspensions and emulsions with edible oil such as cottonseed oil, coconut oil, almond oil, or peanut oil.
  • a composition intended for parenteral administration may also include conventional additives such as stabilizers, buffers, preservatives, or dispersing or suspending agents, for example, antioxidants such as methylhydroxybenzoate or similar additives.
  • Dispersing or suspending agents that can be used for aqueous suspensions include synthetic or natural gums, such as tragacanth, alginate, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose, and polyvinylpyrrolidone.
  • the ratio of a cyclohexanehexol especially a scyllo-inositol compound to secretase inhibitor is selected to augment the activity of the scyllo-inositol compound or beta-secretase inhibitor.
  • the ratio of a cyclohexanehexol and a secretase inhibitor is from about 1 : 1 to 1 :110, 1:1 to 1:100, 1:1 to 1 :75, 1:1 to 1:50, 1:1 to 1:25, 1 :1 to 1 :10, 1:1 to 1:5, and 1:1.
  • the ratio of secretase inhibitor to a cyclohexanehexol is from about 1 : 1 to 1 : 110, 1 :1 to 1 :100, 1 :1 to 1 :75, 1 :1 to 1 :50, 1 :1 to 1 :25, 1 :1 to 1 :10, and 1 :1 to 1 :5.
  • This invention provides a conjugate comprising a cyclohexanehexol, especially a scyllo-inositol compound linked to a secretase inhibitor, especially a beta-secretase inhibitor.
  • the invention also relates to isolated covalent conjugates of the invention, and compositions comprising covalent conjugates of the invention.
  • Conjugates of a cyclohexanehexol, especially a scyllo-inositol compound and a secretase inhibitor may be conjugated or linked with an intermediate spacer or linker.
  • a suitable spacer or linker may be a mono- or disaccharide, an amino acid, a sulfate, a succinate, an acetate, or an oligomeric polymeric spacer or linker comprising one or more of such moieties.
  • the invention also provides methods of preparing the above covalent conjugates that result in conjugates with improved pharmacokinetic properties, biological activity, and beneficial effects.
  • the methods comprise incubating or reacting the cyclohexanehexol compound with the secretase inhibitor under conditions that allow formation of a covalent linkage between the two compounds.
  • the invention therefore contemplates a process for preparing a covalent conjugate comprising a cyclohexanehexol covalently bonded or linked to a secretase inhibitor, the process comprising: incubating or reacting the cyclohexanehexol compound with a secretase inhibitor under conditions and at a pH and for a time sufficient for formation of a covalent bond or linkage between the cyclohexanehexol and secretase inhibitor; and isolating the covalent conjugate.
  • the above process for preparing a conjugate comprising a cyclohexanehexol compound and a secretase inhibitor can provide a conjugate with a substantial amount of a cyclohexanehexol compound covalently linked to the secretase inhibitor.
  • the invention further relates to a pharmaceutical formulation of a substantially pure covalent conjugate comprising a cyclohexanehexol compound covalently linked to a secretase inhibitor which provides beneficial effects preferably sustained beneficial effects compared to the cyclohexanehexol compound or secretase inhibitor alone.
  • a pharmaceutical formulation is provided consisting essentially of covalent conjugates comprising a cyclohexanehexol compound covalently linked without an intermediate spacer or linker to a secretase inhibitor.
  • a pharmaceutical formulation is provided consisting essentially of covalent conjugates comprising a cyclohexanehexol covalently linked with an intermediate spacer or linker to a beta-secretase inhibitor.
  • Compounds, compositions or conjugates of the invention may be sterilized by, for example, filtration through a bacteria retaining filter, addition of sterilizing agents to the composition, irradiation of the composition, or heating the composition.
  • the compounds or compositions of the present invention may be provided as sterile solid preparations e.g. lyophilized powder, which are readily dissolved in sterile solvent immediately prior to use.
  • compositions or conjugates After pharmaceutical compositions or conjugates have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated disease or condition.
  • labeling would include amount, frequency, and method of administration.
  • a cyclohexanehexol compound in particular a scyllo-inositol compound may be in a form suitable for administration as a dietary supplement.
  • a supplement may optionally include inactive ingredients such as diluents or fillers, viscosity-modifying agents, preservatives, flavorings, colorants, or other additives conventional in the art.
  • inactive ingredients such as diluents or fillers, viscosity-modifying agents, preservatives, flavorings, colorants, or other additives conventional in the art.
  • conventional ingredients such as beeswax, lecithin, gelatin, glycerin, caramel, and carmine may be included.
  • the dietary supplement may be provided as a liquid dietary supplement (e.g., a dispensable liquid) or alternatively the compositions may be formulated as granules, capsules or suppositories.
  • the liquid supplement may include a number of suitable carriers and additives including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like.
  • the compositions of the present invention are formulated in admixture with a pharmaceutically acceptable carrier.
  • a dietary supplement may be formulated as a beverage, but may be formulated in granule, capsule or suppository form.
  • a supplement may be presented in the form of a softgel which is prepared using conventional methods.
  • a softgel typically includes a layer of gelatin encapsulating a small quantity of the supplement.
  • a supplement may also be in the form of a liquid-filled and sealed gelatin capsule, which may be made using conventional methods.
  • a dietary supplement comprising a cyclohexanehexol compound, in particular a scyllo-inositol compound, in capsule, granule or suppository form
  • one or more cyclohexanehexol compound, in particular scyllo-inositol compound may be intimately admixed with a pharmaceutically acceptable carrier according to conventional formulation techniques.
  • suitable carriers and additives such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be included.
  • kits comprising a cyclohexanehexol especially a scyllo-inositol compound and a secretase inhibitor, especially a beta-secretase inhibitor, or a pharmaceutical composition or conjugate of the invention.
  • the kit can be a package which houses a container which contains a composition of the invention and also houses instructions for administering the composition to a subject.
  • a kit may contain a single dosage form or it may contain two dosage forms i.e. one for each compound to be administered.
  • the kit comprises a fixed ratio dosage of a scyllo-inositol compound and a beta-secretase inhibitor.
  • a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of a pharmaceutical composition of the invention to provide a beneficial effect, in particular a sustained beneficial effect.
  • Associated with such container(s) can be various written materials such as instructions for use, or a notice in the form prescribed by a governmental agency regulating the labeling, manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
  • the invention contemplates the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, a composition or conjugate of the invention for treating a disease, in particular preventing, and/or ameliorating disease severity, disease symptoms, and/or periodicity of recurrence of a disease disclosed herein.
  • the invention also contemplates preventing and/or treating diseases in mammals using a combination of one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta- secretase inhibitor, compositions, conjugates or treatments of the invention.
  • the present invention in embodiments may provide a composition comprising one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor that provides beneficial effects for example, greater solubility, stability, efficacy, potency, and/or utility, in particular greater solubility and stability.
  • Greater efficacy and potency of a treatment of the invention in some aspects may improve the therapeutic ratio of treatment, reducing untoward side effects and toxicity.
  • Selected methods of the invention may also improve long-standing disease (e.g., Alzheimer's disease) even when treatment is begun long after the appearance of symptoms.
  • Prolonged efficacious treatment may be achieved in accordance with the invention following administration of one or more cyclohexanehexol and a secretase inhibitor, or composition of the invention.
  • a composition or method of the invention may provide beneficial effects including an improvement or lessening in decline in biochemical disease marker progression, plaque pathology, quality of life indicators or combinations of any disease parameters.
  • the invention provides a method of preventing or reversing conformationally altered protein assembly or aggregation in an animal that includes introducing one or more cyclohexanehexol and one or more secretase including, their analogs, or derivatives thereof, or a composition or conjugate of the invention, to the conformationally altered protein.
  • a method of preventing or reversing conformationally altered protein assembly or aggregation in an animal includes introducing one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase or a composition or conjugate of the invention, to the conformationally altered protein.
  • a method of treating conformationally altered protein assembly or aggregation in an animal includes administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase or compositions or conjugates of the invention.
  • the invention provides a method for amelioriating progression of a disorder and/or disease or obtaining a less severe stage of a disease in a subject suffering from such disease (e.g. Alzheimer's disease) comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo- inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • a method for amelioriating progression of a disorder and/or disease or obtaining a less severe stage of a disease in a subject suffering from such disease e.g. Alzheimer's disease
  • administering a therapeutically effective amount of one or more
  • the invention in another aspect, relates to a method of delaying the progression of a disease (e.g. Alzheimer's disease) comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo- inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • a disease e.g. Alzheimer's disease
  • the invention relates to a method of increasing survival of a subject suffering from a disorder and/or disease comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo- inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention relates to a method of improving the lifespan of a subject suffering from a disorder and/or disease (e.g., Alzheimer's disease) comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • a disorder and/or disease e.g., Alzheimer's disease
  • aspects of the invention provide improved methods and compositions for use of one or more cyclohexanehexol and one or more secretase for sustained treatment of a disease (e.g., Alzheimer's disease).
  • the present invention in an embodiment provides a composition comprising one or more cyclohexanehexol and one or more secretase that achieve greater efficacy, potency, and utility.
  • the greater efficacy can be shown by improving or reversing cognitive decline and/or survival in Alzheimer's disease with treatment resulting in sustained improvement and/or increased survival after ceasing treatment.
  • the invention provides a method of improving memory of a healthy subject or the memory of a subject with age impaired memory by administering an effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the present invention further relates to a method for improving memory, especially short-term memory and other mental dysfunction associated with the aging process comprising administering an effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • a method for treating a mammal in need of improved memory comprising the step of administering to the mammal an effective memory-improving amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a dietary supplement comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, or anutraceutically acceptable derivative thereof, and one or more secretase inhibitor, especially a beta-secretase inhibitor.
  • a method for treating in a subject a condition of the central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence comprising administering to the subject a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention has particular applications in treating a disease characterized by amyloid deposition, in particular an amyloidoses, more particularly Alzheimer's disease.
  • the invention relates to a method of treatment comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo- inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle, which upon administration to a subject with symptoms of a disease characterized by amyloid deposition, more particularly Alzheimer's disease, produces beneficial effects, preferably sustained beneficial effects.
  • beneficial effects are evidenced by one or more of the following: disruption of aggregated A ⁇ or A ⁇ oligomers, increased or restored long term potentiation, and/or maintenance of or increased synaptic function, and/or, reduced cerebral accumulation of A ⁇ , deposition of cerebral amyloid plaques, soluble A ⁇ oligomers in the brain, glial activity, inflammation, and/or cognitive decline.
  • the invention provides a method involving administering to a subject a therapeutic compound of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle which inhibit amyloid formation, deposition, accumulation and/or persistence, and/or which cause dissolution/disruption of pre-existing amyloid.
  • a combination of a cyclohexanehexol compound(s) and secretase inhibitor(s) or compositions of the invention may be used for inhibiting amyloidosis in disorders in which amyloid deposition occurs.
  • the invention provides a method for treating in a subject a condition associated with an amyloid interaction that can be disrupted or dissociated with one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor especially a beta-secretase inhibitor, comprising administering to the subject a therapeutically effective amount of one or more cyclohexanehexol, especially scyllo-inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo- inosito
  • the invention provides a method for preventing, reversing, reducing or inhibiting amyloid protein assembly, enhancing clearance of amyloid deposits, or slowing deposition of amyloid deposits in a subject comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta- secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a method for preventing, reversing, reducing or inhibiting amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity in a subject comprising administering to the subject a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more scyllo-inositol compound and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a therapeutic method which comprises identifying a patient diagnosed with a neurodegenerative disorder (such as Alzheimer's disease or MCI) and treating the patient with an effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention.
  • a neurodegenerative disorder such as Alzheimer's disease or MCI
  • a patient can be diagnosed with a disease such as a neurodegenerative disorder using a suitable combination of tests and observations.
  • criteria that indicate a likelihood of mild to moderate Alzheimer's disease include a score of about 15 to about 26 on the MMSE test or a decline in cognitive function.
  • the invention provides a prophylactic method which comprises identifying a patient in need of prophylaxis against a neurodegenerative disorder (such as Alzheimer's disease or MCI) or the worsening of one or more symptoms of such disorder, and treating the patient with an effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor or a composition or conjugate of the invention.
  • a neurodegenerative disorder such as Alzheimer's disease or MCI
  • Patients in need of prophylaxis can be assessed by monitoring assayable disease markers (e.g. scyllo-inositol), detection of genes conferring a predisposition to the disease, and other risk factors such as age, diet, and other associated diseases.
  • assayable disease markers e.g. scyllo-inositol
  • detection of genes conferring a predisposition to the disease e.g. scyllo-inositol
  • other risk factors such as age, diet, and other associated diseases.
  • a patient desiring prophylaxis against a disease e.g., Alzheimer's disease
  • the worsening of one or more symptoms of such a disease can be treated with a combination, conjugate or method disclosed herein prior to onset of symptoms of the disease or just at the beginning stages of disease
  • the invention provides a method for increasing or maintaining synaptic function in a subject comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a method for treating mild cognitive impairment (MCI) comprising administering a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • MCI mild cognitive impairment
  • the invention provides a method of reducing or reversing amyloid deposition and neuropathology after the onset of cognitive deficits and amyloid plaque neuropathology in a subject comprising administering to the subject a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo- inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle.
  • the invention provides a method of reducing or reversing amyloid deposition and neuropathology after the onset of cognitive deficits and amyloid plaque neuropathology in a subject comprising administering to the subject an amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutically acceptable salts thereof, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, and a pharmaceutically acceptable carrier, excipient, or vehicle effective to reduce or reverse amyloid deposition and neuropathology after the onset of cognitive deficits and amyloid plaque neuropathology.
  • Particular aspects of the invention relate to a method for treating Alzheimer ' s disease comprising contacting A ⁇ , A ⁇ aggregates, or A ⁇ oligomers in particular A ⁇ 40 or A ⁇ 40 aggregates or oligomers and/or A ⁇ 42 or A ⁇ 42 aggregates or oligomers, in a subject with a therapeutically effective amount of one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention.
  • the invention provides a method for treating Alzheimer' s disease by providing one or more cyclohexanehexol, especially scyllo-inositol compound, and a secretase inhibitor, or a composition or conjugate of the invention, in an amount sufficient to disrupt aggregated A ⁇ or A ⁇ oligomers for a prolonged period following administration.
  • the invention provides a method for treating Alzheimer's disease in a patient in need thereof which includes administering to the individual one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention, in a dose(s) sufficient to increase or restore long term potentiation and/or maintain synaptic function.
  • the invention provides a method for treating Alzheimer's disease comprising administering, preferably orally or systemically, amounts of a cyclohexanehexol, especially scyllo-inositol compound, and a secretase inhibitor, or a composition or conjugare of the invention, to a mammal, to reduce cerebral accumulation of A ⁇ , deposition of cerebral amyloid plaques, soluble A ⁇ oligomers in the brain, glial activity, and/or inflammation for a prolonged period following administration.
  • a cyclohexanehexol especially scyllo-inositol compound, and a secretase inhibitor, or a composition or conjugare of the invention
  • the invention in an embodiment provides a method for treating Alzheimer's disease, the method comprising administering to a mammal in need thereof one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention, in an amount(s) sufficient to reduce cognitive decline, especially for a prolonged period following administration, thereby treating the Alzheimer's disease.
  • the invention in an embodiment provides a method for treating Alzheimer' s disease, the method comprising administering to a mammal in need thereof one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention, in an amount(s) sufficient to increase or maintain synaptic function, especially for a prolonged period following administration, thereby treating the Alzheimer's disease.
  • the invention also provides a method for preventing and/or treating Alzheimer's disease, the method comprising administering to a mammal in need thereof one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, or a composition or conjugate of the invention, in an amount(s) sufficient to disrupt aggregated A ⁇ or A ⁇ oligomers for a prolonged period following administration; and determining the amount of aggregated A ⁇ or A ⁇ oligomers, thereby treating the Alzheimer's disease.
  • the amount of aggregated A ⁇ or A ⁇ oligomers may be measured using an antibody specific for A ⁇ or a scyllo-inositol labeled with a detectable substance such as a radioisotope (e.g., 3 H, 14 C, 35 S, 125 1, 131 I), fluorescent label (e.g., FITC, rhodamine, lanthanide phosphors), luminescent label such as luminal, enzymatic label (e.g., horseradish peroxidase, beta- galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), or biotinyl group.
  • a radioisotope e.g., 3 H, 14 C, 35 S, 125 1, 131 I
  • fluorescent label e.g., FITC, rhodamine, lanthanide phosphors
  • luminescent label such as luminal
  • a compound of the formula I, II, III, IV, V or VI is utilized with a beta-secretase inhibitor or gamma-secretase inhibitor in the treatment of Alzheimer's disease.
  • Alzheimer's disease may be treated by administering a therapeutically effective amount of a compound of the formula I 5 formula II, formula III, formula IV, formula V of formula VI and a beta-secretase inhibitor or gamma-secretase inhibitor.
  • Such treatment may be effective for retarding the degenerative effects of Alzheimer's disease, including specifically, but not exclusively, deterioration of the central nervous system, loss of mental facilities, loss of short term memory, and disorientation.
  • beneficial effects of a composition, conjugate or treatment of the invention can manifest as at least one, two, three, four, five, six, seven, eight, nine, ten, twelve, thirteen, fourteen, fifteen, or all of the following, in particular five or ten or more, more particularly fifteen or more of the following: a) Prevention, increase or restoration of long term potentiation relative to the level in the absence of a cyclohexanehexol, especially a scyllo-inositol compound, and/or secretase inhibitor, especially a beta-secretase inhibitor, after administration to a subject with symptoms of Alzheimer's disease.
  • a cyclohexanehexol especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, induce at least about a 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 15%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% increase in long term potentiation in a subject.
  • a cyclohexanehexol especially a scyllo- inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, induce at least about a 0.05%, 0.1%, 0.5%, 1%, 2%, 5%, 10%, 15%, 20%, 30%, 33%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, 100%, 125%, 150%, 175% or 200% increase in synaptic function in a subject.
  • the combination induces at least about a 2%, 5%, 10%, 15%, 20%,
  • the combination induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% decrease in deposition of cerebral amyloid plaques.
  • a reduction in plaque number A reduction in plaque number.
  • the combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in plaque number. In particular aspects the combination induces a 5-15% or 10- 15% reduction in plaque number. i) A reduction in plaque size.
  • the combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in plaque size.
  • the compounds induce a 5-15% or 10-15% reduction in plaque size.
  • the combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in percent area of the brain covered in plaques. In particular aspects the combination induces a 5-15% or 10-15% reduction in percent area of the brain covered in plaques.
  • k) A reduction in soluble A ⁇ oligomers in the brain, relative to the levels measured in the absence of a combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in subjects with symptoms of Alzheimer's disease.
  • the combination induces at least about a 2%, 5%, 10%, 15%, 20%,
  • a combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in A ⁇ 40.
  • the combination induces a 10-50%, 20-45%, or 25- 35% reduction in brain levels of A ⁇ 40.
  • a reduction in brain levels of A ⁇ 42 A reduction in brain levels of A ⁇ 42.
  • a combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% reduction in A ⁇ 42.
  • the combination induces a 10-50%, 15-40%, or 20- 25% reduction in brain levels of A ⁇ 42.
  • n) A reduction in glial activity in the brain, relative to the levels measured in the absence of a combination of a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, in subjects with symptoms of Alzheimer's disease.
  • the combination induces at least about a 2%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%,
  • glial activity o) Maintenance of synaptic function at about normal for a prolonged period of time, in particular for at least 5 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 14 weeks, 16 weeks, 20 weeks, 24 weeks, 30 weeks, 40 weeks, 52 weeks, or 78 weeks, more particularly, 2 to 4 weeks, 2 to 5 weeks, 3 to 5 weeks, 2 to 6 weeks, 2 to 8 weeks, 2 to 10 weeks, 2 to 12 weeks, 2 to 16 weeks, 2 to 20 weeks, 2 to 24 weeks, 2 weeks to 12 months, or 2 weeks to 24 months following treatment.
  • a reduction or slowing of the rate of disease progression in a subject with Alzheimer's disease In particular a reduction or slowing of cognitive decline in a subject with Alzheimer's disease.
  • q Prevention, reduction or slowing of cognitive deficits or improvement of cognitive abilities.
  • r Prevention, reduction in or slowing of amyloid angiopathy,
  • s A reduction in accelerated mortality.
  • t An increase in survival in a subject with symptoms of Alzheimer's disease.
  • beneficial effects of a cyclohexanehexol and secretase, composition, conjugate, or treatment of the invention can manifest as (a) and (b); (a), (b) and
  • a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutical compositions, conjugates and methods of the invention can be selected that have statistically significant beneficial effects, in particular one or more statistically significant beneficial effects of (a) through (t) above.
  • a cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor, pharmaceutical compositions, conjugates and methods of the invention can also be selected that have sustained beneficial effects, in particular statistically significant sustained beneficial effects.
  • a combination treatment or a pharmaceutical composition is provided with statistically significant sustained beneficial effects, in particular sustained beneficial effects of one or more of (a) through (t) above, comprising a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor.
  • sustained beneficial effects of one or more of (a) through (t) above, comprising a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and a secretase inhibitor, especially a beta-secretase inhibitor.
  • one or more of the beneficial effects provide enhanced therapeutic effects compared with conventional therapies.
  • the present invention also includes methods of using one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta- secretase inhibitor or compositions of the invention in combination treatments with one or more additional therapeutic agents including without limitation other inhibitors of beta-sheet aggregation/fibrillogenesis/ADDL formation (e.g. Alzhemed), NMDA antagonists (e.g. memantine), anti-oxidants (e.g. Vitamin E), hormones (e.g. estrogens), nutrients and food supplements (e.g. Gingko biloba), statins and other cholesterol lowering drugs (e.g.
  • Lovastatin and Simvastatin acetylcholinesterase inhibitors (e.g. donezepil), muscarinic agonists (e.g. AF 102B (Cevimeline, EVOXAC), AFl 50(S), and AF267B), antipsychotics (e.g. haloperidol, clozapine, olanzapine), anti-depressants including tricyclics and serotonin reuptake inhibitors (e.g. Sertraline and Citalopram Hbr), immunotherapeutics and antibodies to A ⁇ (e.g.
  • ELAN AN- 1792 ELAN AN- 1792
  • vaccines e.g., inhibitors of kinases (CDK5, GSK3 ⁇ , GSK3 ⁇ ) that phosphorylate TAU protein (e.g. Lithium chloride), inhibitors of kinases that modulate A ⁇ production (GSK3 ⁇ , GSK3 ⁇ , Rho/ROCK kinases) (e.g. lithium Chloride and Ibuprofen), drugs that upregulate neprilysin (an enzyme which degrades A ⁇ ); drugs that upregulate insulin degrading enzyme (an enzyme which degrades A ⁇ ), agents that are used for the treatment of complications resulting from or associated with a disease, or general medications that treat or prevent side effects.
  • inhibitors of kinases CDK5, GSK3 ⁇ , GSK3 ⁇
  • phosphorylate TAU protein e.g. Lithium chloride
  • inhibitors of kinases that modulate A ⁇ production e.g. lithium Chloride and Ibu
  • the present invention also includes methods of using the compositions of the invention in combination treatments with one or more additional treatments including without limitation gene therapy and/or drug based approaches to upregulate neprilysin (an enzyme which degrades A ⁇ ), gene therapy and/or drug based approaches to upregulate insulin degrading enzyme (an enzyme which degrades A ⁇ ), or stem cell and other cell-based therapies.
  • gene therapy and/or drug based approaches to upregulate neprilysin an enzyme which degrades A ⁇
  • gene therapy and/or drug based approaches to upregulate insulin degrading enzyme an enzyme which degrades A ⁇
  • stem cell and other cell-based therapies include stem cell and other cell-based therapies.
  • compositions comprising a combination of active ingredients in accordance with this aspect of the invention.
  • a combination therapy of the invention optionally with one or more additional therapeutic may provide an additive or synergistic effect, in particular synergistic effect, in one or more of the following: preventing, reducing, reversing or inhibiting A ⁇ fibril assembly or aggregation, A ⁇ toxicity, A ⁇ 42 levels, abnormal protein folding, aggregation, amyloid formation, deposition, accumulation or persistence, and/or amyloid lipid interactions, and/or acceleration of disassembly of preformed fibrils.
  • a combination therapy of the invention optionally with one or more additional therapeutic may provide a synergistic effect in one or more of the following: disrupting aggregated A ⁇ or A ⁇ oligomers; increasing or restoring long term potentiation; maintaining synaptic function; inhibiting, reducing or reversing A ⁇ -induced progressive cognitive decline and cerebral amyloid plaque pathology; improving cognition; reducing cerebral accumulation of A ⁇ ; reducing deposition of cerebral amyloid plaques; reducing soluble A ⁇ oligomers (e.g. A ⁇ 42) in the brain and/or body fluids; reducing glial activity; reducing inflammation and/or cognitive decline.
  • a combination therapy of the invention with one or more additional therapeutic may be particularly effective for treating and preventing neurodegenerative disorders especially Alzheimer's disease.
  • the invention contemplates the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta- secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, for the preparation of a medicament in treating a disease.
  • the invention also contemplates the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, for the preparation of a medicament for preventing and/or treating diseases.
  • the invention additionally provides uses of one or more cyclohexanehexol, especially scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, in the preparation of medicaments for the prevention and/or treatment of diseases disclosed herein.
  • the medicaments provide beneficial effects, preferably sustained beneficial effects following treatment.
  • the medicament may be in a form for consumption by a subject such as a pill, tablet, caplet, soft and hard gelatin capsule, lozenge, sachet, cachet, vegicap, liquid drop, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium) suppository, sterile injectable solution, and/or sterile packaged powder for inhibition of amyloid formation, deposition, accumulation, and/or persistence, regardless of its clinical setting.
  • a subject such as a pill, tablet, caplet, soft and hard gelatin capsule, lozenge, sachet, cachet, vegicap, liquid drop, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium) suppository, sterile injectable solution, and/or sterile packaged powder for inhibition of amyloid formation, deposition, accumulation, and/or persistence, regardless of its clinical setting.
  • the invention relates to the use of a therapeutically effective amount of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, for preparation of a medicament for providing therapeutic effects, in particular beneficial effects, preferably sustained beneficial effects, in treating a disease.
  • the invention provides the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound and one or more secretase inhibitor, especially a beta-secretase inhibitor, for the preparation of a medicament for prolonged or sustained treatment of Alzheimer's disease.
  • the invention provides the use of one or more cyclohexanehexol, especially a scyllo-inositol compound, and one or more secretase inhibitor, especially a beta-secretase inhibitor, or a composition comprising one or more cyclohexanehexol, especially a scyllo-inositol compound and one or more secretase inhibitor, especially a beta-secretase inhibitor, for preparation of a pharmaceutical composition to be employed through oral administration for treatment of a disorder characterized by abnormal protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence.
  • Therapeutic efficacy and toxicity of compositions, conjugates, and methods of the invention may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals such as by calculating a statistical parameter such as the ED 50 (the dose that is therapeutically effective in 50% of the population) or LD 50 (the dose lethal to 50% of the population) statistics.
  • the therapeutic index is the dose ratio of therapeutic to toxic effects and it can be expressed as the ED 50 /LD 50 ratio.
  • Pharmaceutical compositions which exhibit large therapeutic indices are preferred.
  • One or more of the therapeutic effects, in particular beneficial effects disclosed herein can be demonstrated in a subject or disease model. For example, beneficial effects may be demonstrated in a model described in the Examples herein, in particular beneficial effects may be demonstrated in a TgCRND 8 mouse with symptoms of Alzheimer's disease.
  • Cyclohexanehexol, secretase inhibitors, conjugates, and compositions of the present invention can be administered by any means that produce contact of the active agent(s) with the agent's sites of action in the body of a subject or patient to produce a therapeutic effect, in particular a beneficial effect, in particular a sustained beneficial effect.
  • the active ingredients can be administered simultaneously or sequentially and in any order at different points in time to provide the desired beneficial effects.
  • a cyclohexanehexol, secretase inhibitor, and/or composition of the invention can be formulated for sustained release, for delivery locally or systemically. It lies within the capability of a skilled physician or veterinarian to select a form and route of administration that optimizes the effects of the compositions and treatments of the present invention to provide therapeutic effects, in particular beneficial effects, more particularly sustained beneficial effects.
  • Cyclohexanehexols, secretase inhibitors, conjugates, and/or compositions may be administered in oral dosage forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular forms, all utilizing dosage forms well known to those of ordinary skill in the pharmaceutical arts.
  • Cyclohexanehexols, secretase inhibitors, conjugates, and/or compositions may be administered by intranasal route via topical use of suitable intranasal vehicles, or via a transdermal route, for example using conventional transdermal skin patches.
  • a dosage protocol for administration using a transdermal delivery system may be continuous rather than intermittent throughout the dosage regimen.
  • a sustained release formulation can also be used for the therapeutic agents.
  • the cyclohexanehexols, secretase inhibitors, conjugates, and/or compositions are administered by peripheral administration, in particular by intravenous administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, oral administration, topical administration, transmucosal administration, or pulmonary administration.
  • An amount of a cyclohexanehexol, secretase inhibitor, conjugate, and/or composition which will be effective in the treatment of a particular disease to provide effects, in particular beneficial effects, more particularly sustained beneficial effects, will depend on the nature of the disease, and can be determined by standard clinical techniques.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease, and should be decided according to the judgment of the practitioner and each patient's circumstances.
  • the dosage regimen of the invention will vary depending upon known factors such as the pharmacodynamic characteristics of the agents and their mode and route of administration; the species, age, sex, health, medical condition, and weight of the patient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, the route of administration, the renal and hepatic function of the patient, and the desired effect.
  • Suitable dosage ranges for administration are particularly selected to provide therapeutic effects, in particular beneficial effects, more particularly sustained beneficial effects.
  • a dosage range is generally effective for triggering the desired biological responses.
  • the dosage ranges for the cyclohexanehexol are generally about 0.1 mg to about 2 kg per kg per day, about 0.5 mg to about 2 g per kg per day, about 1 mg to about 1 g per kg per day, about 1 mg to about 200 mg per kg per day, about 1 mg to about 100 mg per kg per day, about 10 mg to about 100 mg per kg, about 30 mg to about 70 mg per kg per day, about 1 mg to about 50 mg per kg per day, about 2 to about 50 mg/kg/day, about 2 mg to about 40 mg per kg, or about 3 mg to 30 mg per kg per day.
  • the dosage ranges of a cyclohexanehexol, in particular a scyllo-inositol compound, administered once twice, three times or more daily, especially once or twice daily are about 1 to about 100 mg/kg, 1 to about 90 mg/kg, 1 to about 80 mg/kg, 1 to about 75 mg/kg, 1 to about 70 mg/kg, 1 to about 60 mg/kg, 1 to about 50 mg/kg, 1 to about 40 mg/kg, 1 to about 35 mg/kg, 2 to about 35 mg/kg, 2.5 to about 30 mg/kg, 3 to about 30 mg/kg, 3 to about 20 mg/kg, or 3 to about 15 mg/kg.
  • the required dose of cyclohexanehexol, in particular scyllo-inositol, administered twice daily is about 1 to about 50 mg/kg, 1 to about 40 mg/kg, 2.5 to about 40 mg/kg, 3 to about 40 mg/kg, 3 to about 35 mg/kg, most preferably about 3 to about 30 mg/kg.
  • the required daily dose of cyclohexanehexol, in particular scyllo-inositol is about 1 to about 80 mg/kg and within that range about 1 to about 70 mg/kg, about 1 to about 65 mg/kg, about 2 to about 70 mg/kg, about 3 to about 70 mg/kg, about 4 to about 65 mg/kg, about 5 to about 65 mg/kg, or about 6 to about 60 mg/kg.
  • the required dose of cyclohexanehexol, in particular a scyllo-inositol compound, administered twice daily is about 1 to about 50 mg/kg, 1 to about 40 mg/kg, 2.5 to about 40 mg/kg, 3 to about 40 mg/kg, 3 to about 35 mg/kg, most preferably about 3 to about 30 mg/kg.
  • the required daily dose of cyclohexanehexol, in particular a scyllo-inositol compound is about 1 to about 80 mg/kg and within that range 1 to about 70 mg/kg, 1 to about 65 mg/kg, 2 to about 70 mg/kg, 3 to about 70 mg/kg, 4 to about 65 mg/kg, 5 to about 65 mg/kg, or 6 to about 60 mg/kg.
  • a cyclohexanehexol can be provided once daily, twice daily, in a single dosage unit or multiple dosage units (i.e., tablets or capsules) having about 50 to about 10000 mg, 50 to about 2000 mg, 70 to about 7000 mg, 70 to about 6000 mg, 70 to about 5500 mg, 70 to about 5000 mg, 70 to about 4500 mg, 70 to about 4000 mg, 70 to about 3500 mg, 70 to about 3000 mg, 150 to about 2500 mg, 150 to about 2000 mg, 200 to about 2500, 200 to about 2000 mg, 200 to about 1500 mg, 700 to about 1200 mg, or 1000 mg, in particular 200 to 2000 mg, more particularly 700 to 1200 mg, most particularly 1000 mg.
  • a cyclohexanehexol in particular scyllo-inositol, is administered in an amount sufficient to result in a concentration in the CSF, brain and/or plasma of a subject of between or from about 0.05 ⁇ M to about lOO ⁇ M, 0.05 ⁇ M to about 90 ⁇ M, 0.05 ⁇ M to about 80 ⁇ M, 0.05 ⁇ M to about 70 ⁇ M, 0.05 ⁇ M to about 60 ⁇ M, 0.05 ⁇ M to about 50 ⁇ M, 0.05 ⁇ M to about 40 ⁇ M, 0.05 ⁇ M to about 30 ⁇ M, or 0.05 ⁇ M to about 20 ⁇ M.
  • the concentration of the compound in CSF, brain and/or plasma is between or from about 0.1 ⁇ M to about lOO ⁇ M, 0.1 ⁇ M to about 90 ⁇ M, 0.1 ⁇ M to about 80 ⁇ M, 0.1 ⁇ M to about 70 ⁇ M, 0.1 ⁇ M to about 60 ⁇ M, 0.1 ⁇ M to about 50 ⁇ M, 0.1 ⁇ M to about 40 ⁇ M, 0.1 ⁇ M to about 30 ⁇ M, 0.1 ⁇ M to about 20 ⁇ M, or 0.1 ⁇ M to about lO ⁇ M.
  • a cyclohexanehexol in particular scyllo-inositol, is administered in an amount sufficient to result in peak plasma concentrations, C max , of from or between about 1 to about 125 ⁇ g/ml, 1 to about lOO ⁇ g/ml, 1 to about 90 ⁇ g/ml, 1 to about 80 ⁇ g/ml, 1 to about 70 ⁇ g/ml, 1 to about 60 ⁇ g/ml, 1 to about 50 ⁇ g/ml, 1 to about 40 ⁇ g/ml, 1 to about 30 ⁇ g/ml, 1 to about 20 ⁇ g/ml, 1 to about 10 ⁇ g/ml, 1 to about 5 ⁇ g/ml, 5 to about 125 ⁇ g/ml, 5 to about 100 ⁇ g/ml, 5 to about 70 ⁇ g/ml, 5 to about 50 ⁇ g/ml, 10 to about 100 ⁇ g/ml, 10 to about 90 ⁇ g/ml, 10
  • the C max is between or from about 1-125 ⁇ g/ml, 1-100 ⁇ g/ml, 5-70 ⁇ g/ml, 5-50 ⁇ g/ml, 10-100 ⁇ g/ml, 10-90 ⁇ g/ml, 10-80 ⁇ g/ml, 10-70 ⁇ g/ml, 10-60 ⁇ g/ml, 10- 50 ⁇ g/ml or 10-40 ⁇ g/ml.
  • the C max is from or between about 5 to about 70 ⁇ g/ml, 5 to about 65 ⁇ g/ml, 5 to about 50 ⁇ g/ml, 5 to about 40 ⁇ g/ml, 5 to about 30 ⁇ g/ml, or 5 to about 20 ⁇ g/ml.
  • the time to achieve a desirable plasma level (tj/ 2 ) of a cyclohexanehexol will depend on the individual treated, but is generally between about 1 to 100 hours, 1 to 80 hours, 1 to 70 hours, 1 to 50 hours, 1 to 42 hours, 1 to 33 hours or 3 to 50, 16 to 32, 5 to 30 hours, 10 to 30 hours, 1 to 28 hours, 1 to 25 hours, 10 to 25 hours, 1 to 24 hours, 10 to 24 hours, 13 to 24 hours, 1 to 23 hours, 1 to 20 hours, 1 to 18 hours, 1 to 15 hours, 1 to 14 hours, 1 to 13 hours, 1 to 12 hours, 1 to 10 hours, 1 to 8 hours, 1 to 7 hours, 1 to 5 hours, 1 to 4 hours, 1 to 3 hours or 3 to 5 hours, in particular 1 to 5 hours or 3 to 5 hours.
  • the dosage ranges for a secretase inhibitor are about 5 mg to about 2000 mg, 50 mg to about 1800 mg, 200 mg to about 1600 mg, 100 mg to about 1000 mg, 50 mg to about 1000 mg, 200 mg to about 900 mg, 300 mg to about 900 mg, 5 mg to about 200 mg, 40 mg to about 200 mg, 50 mg to about 200 mg, 60 mg to about 200 mg, 100 mg to about 200 mg, 40 mg to about 150 mg, 60 mg to about 150 mg, 100 mg to about 150 mg, or 100 mg to about 140 mg.
  • a secretase inhibitor can be provided once daily, twice daily, in a single dosage unit or multiple dosage units.
  • a cyclohexanehexol is used in combination with the secretase inhibitor at therapeutically effective weight ratios of between about 1 : 1.5 to 1 : 150, preferably 1 :2 to 1 :50.
  • the combined administration of a cyclohexanehexol (e.g. scyllo-inositol compound(s)) and a secretase inhibitor(s) may require less of the generally-prescribed dose for any of agents when used alone and or may result in less frequent administration of either, both or all agents.
  • compositions of the invention are present in doses that are at least about 1.1 to 1.4, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold lower than the doses of each compound alone required to treat a disease disclosed herein.
  • a composition or treatment of the invention may comprise a unit dosage of at least one cyclohexanehexol (e.g. scyllo-inositol compound) and at least one secretase inhibitor to provide beneficial effects, in particular one or more of the beneficial effects (a) to (t) set out herein.
  • a "unit dosage” or “dosage unit” refers to a unitary i.e., a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active agents as such or a mixture with one or more solid or liquid pharmaceutical excipients, carriers, or vehicles.
  • a subject may be treated with a cyclohexanehexol and secretase inhibitor, or a conjugate or composition of the invention on substantially any desired schedule.
  • a cyclohexanehexol e.g. scyllo-inositol compound
  • secretase inhibitor or a conjugate or composition of the invention may be administered one or more times per day, in particular 1 or 2 times per day, 1, 2, 3, 4, 5 or more times per week, 1 to 20, 1 to 15, 1 to 10 or 1 to 5 times a month or continuously.
  • a subject may be treated less frequently, such as every other day or once a week, or more frequently.
  • a cyclohexanehexol, secretase inhibitor, or a conjugate or composition of the invention may be administered to a subject for about or at least about 1 week, 2 weeks to 4 weeks, 2 weeks to 6 weeks, 2 weeks to 8 weeks, 2 weeks to 10 weeks, 2 weeks to 12 weeks, 2 weeks to 14 weeks, 2 weeks to 16 weeks, 2 weeks to 6 months, 2 weeks to 12 months, 2 weeks to 18 months, or 2 weeks to 24 months, periodically or continuously.
  • a cyclohexanehexol compound(s) and a secretase inhibitor(s) can be administered simultaneously or at separate intervals.
  • the cyclohexanehexol compound(s) and the secretase inhibitor(s) can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition.
  • two or more separate compositions i.e., one containing the cyclohexanehexol compound(s) and the other(s) containing the secretase inhibitor(s), can be administered simultaneously.
  • compositions containing a cyclohexanehexol compound, and a secretase inhibitor(s) are administered on a different schedule.
  • a therapeutically effective interval is a period of time beginning when one of either the (a) cyclohexanehexol, in particular, the scyllo-inositol compound, or (b) secretase inhibitor(s) is (are) administered to a mammal and ending at the limit of the beneficial effect in the treatment of the disease to be treated from the combination of (a) and (b).
  • the methods of administration of the cyclohexanehexol compound(s), and a secretase inhibitor(s) may vary. Thus, any of the agents may be administered rectally, topically, orally, sublingually, or parenterally.
  • mice mice
  • mice mice
  • 30 mg/day of a scyllo-inositol compound and a secretase inhibitor The studies will be repeated using doses of 1 mg/Kg/day- 100mg/Kg/day .
  • Mannitol will be used as a negative control for potential alterations in caloric intake. Controls will also include the scyllo-inositol compound and secretase inhibitor alone. Behavioural tests: Morris Water Maze testing will be performed as described in Janus,C. et al, 2000. After non-spatial pre-training, mice will undergo discrimination training for 5 days with 4-trials per day, followed by a cued visible platform to rule out general motivational, learning deficits and motor problems, and a probe trial to evaluate memory.
  • Data will be subjected to a mixed model of repeated measures analysis of variance (ANOVA) with treatment (untreated, scyllo-inositol compound and secretase inhibitor treated) and genotype (TgCRND8 versus non-Tg) as 'between-subject' factors.
  • ANOVA repeated measures analysis of variance
  • Treatment untreated, scyllo-inositol compound and secretase inhibitor treated
  • genotype TgCRND8 versus non-Tg
  • Brains will be removed and one hemisphere fixed in 4% paraformaldehyde and embedded in paraffin wax in the mid sagittal plane. To generate sets of systematic uniform random sections, 5 ⁇ m serial sections will be collected across the entire hemisphere. Sets of sections at 50 ⁇ m intervals will be used for analyses (10-14 sections/set). Plaques will be identified after antigen retrieval with formic acid, and incubated with primary anti-A ⁇ antibody (Dako M-0872), followed by secondary antibody (Dako StreptABCcomplex/horseradish kit). End products will be visualized with DAB and counter- stained with luxol fast blue.
  • primary anti-A ⁇ antibody Dako M-0872
  • secondary antibody Dako StreptABCcomplex/horseradish kit
  • Amyloid plaque burden will be assessed with Leco IA-3001 image analysis software interfaced with Leica microscope and Hitachi KP-MlU CCD video camera. Openlab imaging software (Improvision, Lexington, MA) will be then used to convert micrographs to binary images for plaque number and plaque area determinations.
  • Vascular amyloid burden will be defined as amyloid originating from or surrounding blood vessels and will be similarly analysed.
  • Hemi-brain samples will be homogenized in a buffered sucrose solution, followed by either 0.4% diethylamine/10OmM NaCl for soluble A ⁇ levels or cold formic acid for the isolation of total A ⁇ . After neutralization, the samples will be diluted and analyzed for A ⁇ 40 and A ⁇ 42 using commercially available kits (BIOSOURCE International). Each hemisphere will be analyzed in triplicate and the mean values ⁇ SEM reported. Western blot analyses will be performed on all fractions using urea gels for A ⁇ species analyses (Wiltfang, J. et al, JNeurochem 81, 481-496 (2002)).
  • a ⁇ will be detected using 6E10 (BIOSOURCE International) and Enhanced Chemiluminenscence (Amersham). Gliosis Quantitation. Five randomly selected, evenly spaced, sagittal sections will be collected from paraformaldehyde-fixed and frozen hemispheres of treated and control mice. Sections will be immunolabelled for astrocytes with anti-rat GFAP IgG 23 (Dako; diluted 1 :50) and for microglia with anti-rat CD68 IgG 2b (Dako; 1 :50). Digital images will be captured using a Coolsnap digital camera (Photometries, Tuscon, Arizona) mounted to a Zeiss, Axioscope 2 Plus microscope.
  • Mouse hemi-brain samples will be homogenized and spun at 109,000 x g, in 2OmM Tris pH7.4, 0.25M sucrose, ImM EDTA and ImM EGTA, and a protease inhibitor cocktail, will be mixed with 0.4%DEA (diethylamine)/l 0OmM NaCl.
  • the supernatants will be analysed for APPs levels by Western blotting using mAb 22Cl 1, while the pellets will be analysed for APP holoprotein with mAb C 1/6.1 as previously described (Janus, 2000; Chishti, M , 2001).
  • Soluble A ⁇ oligomer Analyses The levels of soluble A ⁇ oligomers will be measured by a dot blot assay with anti-oligomer specific antibodies (Kayed, R. et al, Science 300, 486-489 (2003)). Briefly, oligomers will be solubilised from one hemi-brain in PBS in the presence of protease inhibitor cocktail (Sigma). After centrifugation at 78,500 x g for 1 hr at 4°C, the supernatants will be analysed. Protein content will be determined by the BCA protein assay (Pierce).
  • the brain will be rapidly removed and placed in ice cold oxygenated sucrose-CSF containing (in mM): 248 sucrose, 2 KCl, 2 MgSO 4 , 1.24 NaH 2 PO 4 , 1 CaCl 2 , 1 MgCl 2 , 26 NaHCO 3 , 10 D-glucose, pH 7.4, ⁇ 315 mOsmol. (Moyer JR Jr, & Brown TH., JNeurosci Methods.%6, 35-54 (1998)).
  • the hippocampus from each hemisphere will be isolated and 350 ⁇ m coronal sections will be made.
  • the slices will be transferred to a holding chamber containing NaCl-CSF (in mM: 124 NaCl, 2 KCl, 2 MgSO 4 , 1.25 NaH 2 PO 4 , 2 CaCl 2 , 26 NaHCO 3 , 10 D-glucose, pH 7.4, ⁇ 310 mOsmol) and allowed to recover for more than 1 hour.
  • NaCl-CSF in mM: 124 NaCl, 2 KCl, 2 MgSO 4 , 1.25 NaH 2 PO 4 , 2 CaCl 2 , 26 NaHCO 3 , 10 D-glucose, pH 7.4, ⁇ 310 mOsmol
  • a bipolar stimulating electrode (World Precision Inst.) will be placed in the Schaffer collaterals to deliver baseline stimuli and tetani.
  • a borosilicate glass recording electrode (2-4 M ⁇ ) containing ACSF will be positioned approximately 75 - 200 ⁇ m from the stimulating electrode.
  • the intensity of the stimulus (typically between 10-20 ⁇ Amps) will be set to obtain 25-40% of the maximal field potential response.
  • Test stimuli will be delivered at 0.05Hz.
  • 4 tetani (100 Hz for 1 second) will be delivered 5 minutes apart.
  • Field potential responses will be amplified 1 Ox using an Axopatch 200B.
  • the data will be sampled at 10 kHz and filtered at 2kHz. Traces will be analyzed using pClamp 9.2.
  • the slope of the field potential will be estimated using approximately 10-60% of the total response. Synaptophysin Quantification.
  • Synaptophysin immunohistochemical staining will be performed on 3 evenly spaced saggital sections of paraformaldehyde-f ⁇ xed treated and control mice. Sections will be immunolabelled for synaptophysin with anti-synaptophysin IgG (1 :40; Roche, Laval, PQ). Digital images will be captured and analyzed as described above. Within each section, three randomly chosen 100 ⁇ m 2 areas of the CAl region of the hippocampus will be counted for synaptophysin reactive cell bodies and boutons. The results will be expressed as the mean of the number of reactive bodies and boutons per 100 ⁇ m 2 (Phinney, A. et al, Neuroscience 90, 1207-1216 (1999); Hu, L.
  • a scyllo-inositol compound in combination with a secretase inihibitor disclosed herein will be administered to a murine model of Alzheimer's disease (TgCRND8) (Chishti, M. A. etal.J.Biol Chem 276, 21562-21570 (2001); Janus,C. et al, Nature 408, 979-982 (2000)).
  • TgCRND8 a murine model of Alzheimer's disease
  • the TgCRND ⁇ mice and non-transgenic littermates will be assigned to sex- and age-matched cohorts that are then used to test the effectiveness of the combination therapy.
  • mice will be randomly assigned to receive active compounds, mock therapy (mannitol), or no therapy.
  • the endpoints will be cognitive function, brain A ⁇ levels, and neuropathology.
  • the start of treatment of the TgCRND8 mice will be delayed until five months of age.
  • TgCRND ⁇ mice have significant behavioural deficits, accompanied by profuse A ⁇ peptide and plaque burdens (Chishti, M. A. et al, (2001)).
  • TgCRND8 and non-Tg littermates (10 mice per cohort) will be either treated for 28 days with a scyllo-inositol compound and a secretase inhibitor, each compound alone, or are left untreated.
  • the dosage and oral administration of compounds, and the neurochemical and neuropathological assays used for these experiments will be the same as employed in the initial prophylactic experiments. Spatial learning in the transgenic mice will be compared between six month old
  • TgCRND ⁇ mice that have been treated with a compound disclosed herein or that were untreated for 28 days.
  • the performance of six month old TgCRND 8 mice that had been treated with a scyllo-inositol compound and a secretase inhibitor for 28 days is anticipated to result in better behavioural performance.
  • a 28 day course of treatment at 5 months of age is also expected to: 1) reduce brain levels of A ⁇ 40 and A ⁇ 42; and, 2) significantly reduce plaque number, plaque size, and percent area of the brain covered in plaques. The results are expected to demonstrate an additive or synergistic effect compared to each compound alone.
  • a dot blot immunoassay (Kayed, R. et al, Science 300, 486-489 (2003)) will be used to measure levels of A ⁇ oligomers in the brains of treated and untreated TgCRND8 mice.
  • the assay employs an antibody that selectively identifies oligomeric A ⁇ species (Kayed, R. et al, 2003).
  • the levels of soluble A ⁇ oligomers are expected to be significantly reduced in the brain of mice treated with the combination of scyllo-inositol and secretase inhibitor. The results are expected to demonstrate an additive or synergistic effect compared to each compound alone.
  • LTP long term potentiation
  • 7PA2-conditioned medium is pretreated in vitro with a scyllo-inositol compound and a secretase inhibitor there will be enhanced recovery of LTP compared with 7PA2-conditioned media alone or the media with each compound alone.
  • synaptophysin immunoreactivity is a measure of synaptic density, which is correlated to synaptic function.
  • the levels of synaptophysin are expected to be increased.
  • compounds are expected to increase the number of synaptophysin reactive boutons and cell bodies in the CAl region of the hippocampus. The results are expected to demonstrate an additive or synergistic effect compared to each compound alone.
  • Example 2 A scyllo-inositol compound and a secretase inhibitor, in particular a beta-secretase inhibitor, can be tested in an Alternating Lever Cyclic Ratio rat model of Alzheimer's disease (O'Hare, E. et al, Behavior Pharmacology, 7:742-753, (1996); Richardson, RL, et al., Brain Research, 54: 1-10, (2002)).
  • This model has been able to detect cognitive deficits due to direct injection of amyloid- ⁇ oligomers into rat brain.
  • the compounds can be administered concurrent with A ⁇ oligomers known to adversely affect cognition and their ability to counteract the oligomer-induced cognitive decline can be assessed.
  • ACR Alternativing Lever Cyclic Ratio test rats must first learn a complex sequence of lever-pressing requirements in order to earn food reinforcement in a two-lever experimental chamber. Subjects must alternate between two levers by switching to the other lever after pressing the first lever enough to get food rewards. The exact number of presses required for each food reward changes, first increasing from 2 responses per food pellet up to 56 based on the quadratic function, x 2 -x. One cycle is an entire ascending and descending sequence of these lever press requirements (e.g., 2, 6, 12, 20, 30, 42, 56, 56, 42, 30, 20, 12, 6, and 2 presses per food reward). Six such full cycles are presented during each daily session.
  • Errors are scored when the subject perseveres on a lever after pressing enough to get the food reward, i.e., does not alternate (a Perseveration Error), or when a subject switches levers before completing the response requirement on that lever (a Switching Error).
  • Olisomeric A ⁇ Prepared from transfected Chinese Hamster Ovary Cells (7PA2 cells). These cells secrete oligomeric A ⁇ into the culture medium (CM) at physiological levels. A ⁇ oligomers will also be derived from Tg2576 mouse brain and purified by size exclusion chromatography. Samples of oligomeric A ⁇ will be characterized by Western Blot Analysis. Appropriate control compounds will be produced and tested for each active A ⁇ oligomeric configuration.
  • CM culture medium
  • Rats Forty (40) rats will be trained under ALCR for approximately 3 months until their error rates are stable. Training sessions are conducted 5 days each week. Surgery: After training, all rats will receive a single 28 ga. cannula, that will be permanently affixed to the skull, and aimed at the lateral ventricle (divided equally between left and right). Rats will be allowed 5 days to recover from surgery.
  • Test compounds will be tested against A ⁇ oligomers known to disrupt cognitive function. Two general procedures will be incorporated. 1. Test compounds will be incubated with the injectate medium containing A ⁇ oligomers prior to assessing their affect on ALCR. Appropriate control injections will include un-incubated (untreated) A ⁇ oligomers as well as compound injected ICV.
  • hematoxylin and eosin stained sections will be used to evaluate for cannula placement. These same hemibrains will be evaluated for inflammation (neutrophils/lymphocytes/macrophages), gliosis (microglial and astrocytic) and neuron loss using standard hematoxylin and eosin staining as well as specific markers for gliosis as needed.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte d'une manière générale sur de nouvelles compositions et de nouveaux procédés comprenant un cyclohexanehexol et un inhibiteur de la sécrétase. Les compositions et procédés fournissent des effets utiles, en particulier, des effets utiles entretenus, dans le traitement de maladies mettant en jeu un trouble dans le repliement et/ou l'agrégation de protéines, et/ou la formation, le dépôt, l'accumulation ou la persistance d'amyloïdes, telles que la maladie d'Alzheimer et des troubles neurodégénératifs apparentés.
PCT/CA2007/002118 2006-11-24 2007-11-22 Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues WO2008061373A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009537460A JP2010510254A (ja) 2006-11-24 2007-11-22 アルツハイマー病および関連の神経変性疾患のための併用処置
CA002670405A CA2670405A1 (fr) 2006-11-24 2007-11-22 Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues
US12/445,164 US20100292157A1 (en) 2006-11-24 2007-11-22 Combination Treatments for Alzheimer's Disease and Similar Diseases
EP07845583A EP2091566A4 (fr) 2006-11-24 2007-11-22 Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86088406P 2006-11-24 2006-11-24
US60/860,884 2006-11-24

Publications (1)

Publication Number Publication Date
WO2008061373A1 true WO2008061373A1 (fr) 2008-05-29

Family

ID=39429352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2007/002118 WO2008061373A1 (fr) 2006-11-24 2007-11-22 Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues

Country Status (5)

Country Link
US (1) US20100292157A1 (fr)
EP (1) EP2091566A4 (fr)
JP (1) JP2010510254A (fr)
CA (1) CA2670405A1 (fr)
WO (1) WO2008061373A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation
WO2017095250A1 (fr) * 2015-11-30 2017-06-08 Centro De Neurociências E Biologia Celular Inhibiteurs peptidiques de la bace1 permettant le traitement de troubles neurologiques
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10493072B2 (en) 2014-10-24 2019-12-03 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
US11117881B2 (en) 2019-12-20 2021-09-14 Landos Biopharma, Inc. Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
US11197891B2 (en) 2017-11-30 2021-12-14 Landos Biopharma, Inc. Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
US11291648B2 (en) 2018-07-02 2022-04-05 The General Hospital Corporation Powdered formulations of cromolyn sodium and alpha-lactose
US11679095B2 (en) 2016-08-31 2023-06-20 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
WO2024054415A1 (fr) * 2022-09-07 2024-03-14 Eirgen Pharma, Ltd. Association de scyllo-inositol et de flavones

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516563A1 (fr) * 2003-02-27 2004-09-10 Joanne Mclaurin Procedes permettant de prevenir, traiter et diagnostiquer des troubles dans l'agregation des proteines
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2006047544A2 (fr) * 2004-10-22 2006-05-04 Mount Sinai School Of Medecine Of New York University Compositions et procedes de traitement de la maladie d'alzheimer et de troubles associes et procedes favorisant un systeme nerveux sain
CA2588423A1 (fr) * 2004-11-17 2006-05-26 Joanne Mclaurin Preparations comprenant des derives de scyllo-inositol et methodes de traitement de troubles d'agregation proteinique
CA2579188A1 (fr) * 2006-02-17 2007-08-17 Joanne Mclaurin Traitement de maladies associees aux substances amyloides
WO2007101353A1 (fr) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. Formulation de polyalcool de cyclohexane pour le traitement de dysfonctionnents de l'agrégation protéique
WO2007119108A2 (fr) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Composés inositol et leurs utilisations pour traiter des maladies caractérisées par un repliement protéique anormal, une agrégation protéique, ou une formation, un dépôt, une accumulation ou une persistance d'amyloïde

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JP4242925B2 (ja) * 1992-10-05 2009-03-25 バージニア テック インテレクチュアル プロパティース インコーポレイテッド Ｄ−ｃｈｉｒｏ−３−イノソース及び▲（＋）▼−Ｄ−ｃｈｉｒｏ−イノシトールの合成
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
DK0619369T3 (da) * 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
WO1995004711A1 (fr) * 1993-08-11 1995-02-16 Hokko Chemical Industry Co., Ltd. Procede de production de d-chiro-inositol
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
MXPA02003861A (es) * 1999-10-18 2003-07-14 Muscletech Res And Dev Inc Suplemento alimenticio para incrementar la masa sin desarrollar y la fuerza.
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
EP1357912B9 (fr) * 2001-02-06 2012-06-13 QLT Inc. TRAITEMENT PHOTODYNAMIQUE DE LA néovascularisation choroïdienne occulte liée à la DMA
CA2437561A1 (fr) * 2001-02-06 2002-08-15 Qlt Inc. Methode de prevention de la perte de la vue
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
EP2058390B1 (fr) * 2003-10-14 2013-01-23 Hokko Chemical Industry Co., Ltd. Procédé de production de scyllo-inositol
WO2008034244A1 (fr) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. Combinaison d'un cyclohexanehexol et d'un ains pour le traitement des maladies neurodegeneratives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516563A1 (fr) * 2003-02-27 2004-09-10 Joanne Mclaurin Procedes permettant de prevenir, traiter et diagnostiquer des troubles dans l'agregation des proteines
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2006047544A2 (fr) * 2004-10-22 2006-05-04 Mount Sinai School Of Medecine Of New York University Compositions et procedes de traitement de la maladie d'alzheimer et de troubles associes et procedes favorisant un systeme nerveux sain
CA2588423A1 (fr) * 2004-11-17 2006-05-26 Joanne Mclaurin Preparations comprenant des derives de scyllo-inositol et methodes de traitement de troubles d'agregation proteinique
WO2007119108A2 (fr) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Composés inositol et leurs utilisations pour traiter des maladies caractérisées par un repliement protéique anormal, une agrégation protéique, ou une formation, un dépôt, une accumulation ou une persistance d'amyloïde
CA2579188A1 (fr) * 2006-02-17 2007-08-17 Joanne Mclaurin Traitement de maladies associees aux substances amyloides
WO2007101353A1 (fr) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. Formulation de polyalcool de cyclohexane pour le traitement de dysfonctionnents de l'agrégation protéique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASAI M. ET AL.: "The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice", J. NEUROCHEM., vol. 96, no. 2, January 2006 (2006-01-01), pages 533 - 540, XP008109228 *
GHOSH A.K. ET AL.: "E-Secretase as a therapeutic target for inhibitor drugs", CURR. MEDIC. CHEM., vol. 9, 2002, pages 1135 - 1144, XP008109273 *
MCLAURIN J. ET AL.: "Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model", NATURE MEDICINE, vol. 12, 2006, pages 801 - 808, XP008109229 *
See also references of EP2091566A4 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation
US9833420B2 (en) 2003-02-27 2017-12-05 JoAnne McLaurin Methods of preventing, treating, and diagnosing disorders of protein aggregation
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US10245331B2 (en) 2009-01-29 2019-04-02 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US11801316B2 (en) 2009-01-29 2023-10-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10576171B2 (en) 2009-01-29 2020-03-03 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10251961B2 (en) 2009-01-29 2019-04-09 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US11110097B2 (en) 2012-10-25 2021-09-07 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10398704B2 (en) 2012-10-25 2019-09-03 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10406164B2 (en) 2012-10-25 2019-09-10 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10413551B2 (en) 2012-10-25 2019-09-17 The General Hospital Corporation Combination therapies for the treatment of Alzheimer'S disease and related disorders
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US9968618B1 (en) 2012-10-25 2018-05-15 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US11013686B2 (en) 2013-05-23 2021-05-25 The General Hospital Corporation Cromolyn compositions and methods thereof
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US11666669B2 (en) 2013-10-22 2023-06-06 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US10849895B2 (en) 2014-10-24 2020-12-01 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10682349B2 (en) 2014-10-24 2020-06-16 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US11571419B2 (en) 2014-10-24 2023-02-07 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
US10493072B2 (en) 2014-10-24 2019-12-03 Landos Biopharma, Inc. Lanthionine synthetase C-like 2-based therapeutics
WO2017095250A1 (fr) * 2015-11-30 2017-06-08 Centro De Neurociências E Biologia Celular Inhibiteurs peptidiques de la bace1 permettant le traitement de troubles neurologiques
US11679095B2 (en) 2016-08-31 2023-06-20 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US10561612B2 (en) 2017-07-20 2020-02-18 The General Hospital Corporation Powdered formulations of cromolyn sodium and ibuprofen
US11197891B2 (en) 2017-11-30 2021-12-14 Landos Biopharma, Inc. Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
US11291648B2 (en) 2018-07-02 2022-04-05 The General Hospital Corporation Powdered formulations of cromolyn sodium and alpha-lactose
US11117881B2 (en) 2019-12-20 2021-09-14 Landos Biopharma, Inc. Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
US11377437B2 (en) 2019-12-20 2022-07-05 Landos Biopharma, Inc. Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same

Also Published As

Publication number Publication date
CA2670405A1 (fr) 2008-05-29
EP2091566A4 (fr) 2011-07-06
JP2010510254A (ja) 2010-04-02
EP2091566A1 (fr) 2009-08-26
US20100292157A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
EP2091566A1 (fr) Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues
US20100173960A1 (en) The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20140155480A1 (en) Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence
AU2005306531B2 (en) Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
US20100113613A1 (en) cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
US20070197452A1 (en) Treatment of amyloid-related diseases
EP2131839A2 (fr) Compositions et traitements pour des troubles liés à des crises
JP2009526834A (ja) タンパク質凝集の疾患の治療のための組成物および方法
US20110105626A1 (en) Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
CA2579188A1 (fr) Traitement de maladies associees aux substances amyloides
US20100331267A1 (en) Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
US20100144891A1 (en) Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845583

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009537460

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2670405

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007845583

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12445164

Country of ref document: US